{"study_id": 104130, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to compare the safety and efficacy of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treating chronic hepatitis B (CHB), focusing on renal and bone safety and viral suppression.", "results_summary": "TAF showed similar viral suppression to TDF but with higher alanine aminotransferase normalization rates and improved renal and bone safety. Switching from TDF to TAF rapidly improved safety parameters while maintaining virological suppression.", "population_specificity": "Mainly treatment-naive HBeAg-positive or -negative chronic hepatitis B patients, including those previously treated with TDF.", "effective_dosage": "25 mg/day for TAF, 300 mg/day for TDF.", "study_duration": "96 weeks for phase III trials, 48 weeks for the switch study.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:22.296695+00:00"}
{"study_id": 104134, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical characteristics and outcomes of TCM-induced liver injury (TCM-ILI) and estimate its proportion among all drug-induced liver injuries (DILI).", "results_summary": "The study found that TCM-ILI accounted for 25.71% of all DILI cases, with a mortality rate of 4.67% and liver transplantation rate of 2.18%. Male gender, higher aspartate aminotransferase, direct bilirubin, and lower albumin were associated with worse outcomes.", "population_specificity": "Predominantly female and older patients with TCM-induced liver injury.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:22.641631+00:00"}
{"study_id": 104132, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers assessed the efficacy and toxicity profiles of trastuzumab emtansine (T-DM1) in heavily pretreated HER2-positive advanced breast cancer patients, not specifically Alanine.", "results_summary": "The study found that T-DM1 was well tolerated with manageable toxicities (e.g., thrombocytopenia, raised alanine transaminase) and provided a median progression-free survival of 6 months. Alanine transaminase elevation was noted as a grade 3 or 4 toxicity in 8.1% of patients.", "population_specificity": "Hong Kong Chinese patients with HER2-positive advanced breast cancer who had received prior anti-HER2 therapy and cytotoxic chemotherapy.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Study period was from December 2013 to December 2015; individual treatment duration not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:22.938080+00:00"}
{"study_id": 104127, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to determine the safety, tolerability, pharmacokinetics, and disease response of pevonedistat (PEV) in combination with azacitidine (AZA) for treatment-naive AML patients unfit for standard induction therapy.", "results_summary": "The study evaluated the synergistic activity of PEV with AZA in a phase 1b trial, focusing on safety, tolerability, and disease response, but did not report specific outcomes related to Alanine.", "population_specificity": "Patients \u226560 years with treatment-naive AML unfit for standard induction therapy.", "effective_dosage": "PEV 20 or 30 mg/m\u00b2 (frequency not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:25.597567+00:00"}
{"study_id": 104135, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety and efficacy of erlotinib combined with ramucirumab in treating EGFR-mutant stage IV NSCLC, not specifically Alanine.", "results_summary": "The study reported one case of Grade 3 elevated alanine aminotransferase as a dose-limiting toxicity, but overall adverse events were mild and manageable. Median progression-free survival was 17.1 months, showing encouraging clinical activity.", "population_specificity": "Patients with untreated stage IV NSCLC, Eastern Cooperative Oncology Group performance status of 0 to 1, and activating EGFR mutation (exon 19 deletion or exon 21 L858R substitution).", "effective_dosage": "Ramucirumab 10 mg/kg every 2 weeks and erlotinib 150 mg daily.", "study_duration": "Until disease progression or unacceptable toxicity.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:25.795376+00:00"}
{"study_id": 104136, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of a calorie-restricted diet and resveratrol supplementation on metabolic parameters, including alanine aminotransferase (ALT) levels, in patients with NAFLD.", "results_summary": "The study found that a calorie-restricted diet significantly reduced ALT levels, while resveratrol supplementation did not significantly alter ALT or other metabolic markers.", "population_specificity": "90 patients with NAFLD, aged 20-60 years, BMI 25-35 kg/m\u00b2.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:27.242290+00:00"}
{"study_id": 104137, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the prognostic capability of a comorbidity-based model (HepCom score) for predicting mortality and clinical events in HCV patients receiving direct-acting antiviral therapy, including the role of alanine aminotransferase (ALT) as a prognostic factor.", "results_summary": "The study found that ALT, along with cirrhosis, platelet count, and sex, was adjusted for in mortality analysis, but the primary focus was on the HepCom score's predictive ability for one- and two-year mortality. The HepCom score, incorporating Charlson comorbidity index, age, and liver function markers, effectively identified high- and low-risk mortality groups.", "population_specificity": "Patients with HCV infection, irrespective of liver fibrosis stage, from 14 Spanish University Hospitals.", "effective_dosage": "Not specified", "study_duration": "Up to two years of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:29.310805+00:00"}
{"study_id": 104138, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of amino acid (AA) preparations, including alanine, in treating nonalcoholic steatohepatitis (NASH) in Chornobyl disaster sufferers by assessing metabolic changes and liver function.", "results_summary": "AA preparations normalized aminotransferase levels, reduced cholestasis symptoms (significant decreases in bilirubin and alkaline phosphatase), improved fat and carbohydrate metabolism (lowered beta lipoproteins, triglycerides, and glucose), and enhanced antioxidant protection.", "population_specificity": "104 male Chornobyl disaster sufferers with NASH.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.075757+00:00"}
{"study_id": 104139, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine and compare plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations of levonadifloxacin following oral administration of alalevonadifloxacin (an l-alanine ester prodrug) in healthy adults.", "results_summary": "The study measured levonadifloxacin concentrations in plasma, ELF, and AM samples using LC-MS/MS after oral dosing of alalevonadifloxacin (1,000 mg twice daily for 5 days). Noncompartmental pharmacokinetic parameters and penetration ratios were calculated from AUC data.", "population_specificity": "30 healthy adult subjects", "effective_dosage": "1,000 mg twice daily", "study_duration": "5 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.421952+00:00"}
{"study_id": 104141, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of AMT-060, an AAV5-based gene therapy, for treating hemophilia B by enabling endogenous FIX production.", "results_summary": "The study enrolled 10 adults with severe hemophilia B and found no AAV5-neutralizing antibodies in participants, suggesting potential for successful gene transfer. Efficacy was implied by the focus on endogenous FIX activity, but specific outcomes were not detailed in the abstract.", "population_specificity": "Adults with hemophilia B (FIX \u22642% of normal) and severe-bleeding phenotype.", "effective_dosage": "Single dose of 5 \u00d7 10^12 (units not specified).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:31.558529+00:00"}
{"study_id": 104140, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the role of serum CK18 and HGF levels in obstructive jaundice patients before and after treatment, focusing on liver injury markers including alanine aminotransferase.", "results_summary": "The study found significant decreases in alanine aminotransferase and other liver injury markers post-treatment, suggesting reduced liver apoptosis after biliary decompression. HGF and CK18 levels were also altered in obstructive jaundice patients compared to healthy controls.", "population_specificity": "40 obstructive jaundice patients and 40 healthy controls.", "effective_dosage": "Not specified", "study_duration": "Blood samples were taken before and 7 days after intervention.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:32.339041+00:00"}
{"study_id": 104142, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess the efficacy and safety of Fuzheng Huayu (FZHY) capsule, which includes Alanine, as an adjuvant treatment for HBV-related liver cirrhosis.", "results_summary": "FZHY capsule improved liver function markers (ALT, AST, TBIL), fibrosis indicators (PIIIP, HA, LN, IV-C), and clinical outcomes (Child-Pugh score, portal vein diameter, spleen thickness, HBV-DNA negative conversion rate) with no serious adverse reactions. However, the study noted the need for larger, well-designed trials to confirm these findings.", "population_specificity": "Patients with HBV-associated liver cirrhosis (1,769 participants across 19 studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:34.714644+00:00"}
{"study_id": 104143, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were investigating the effects of duvelisib (IPI-145), a PI3K-\u03b4/\u03b3 inhibitor, on malignant and nonmalignant immune cells in patients with relapsed or refractory PTCL and CTCL.", "results_summary": "The study found overall response rates of 50.0% in PTCL and 31.6% in CTCL patients, suggesting potential clinical efficacy of duvelisib in these populations. The abstract does not mention Alanine or its effects.", "population_specificity": "Patients with relapsed or refractory peripheral T-cell lymphoma (PTCL, n = 16) and cutaneous T-cell lymphoma (CTCL, n = 19).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:34.847043+00:00"}
{"study_id": 104144, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety, efficacy, and clinical effectiveness of Entecavir (ETV) in Korean patients with chronic hepatitis B (CHB).", "results_summary": "The study found that ETV was well tolerated, with a low incidence of adverse events (7.57%) and serious adverse events (0.27%). The overall clinical effectiveness rate was 96.53%, with marked improvement or improvement in patient symptoms.", "population_specificity": "Korean patients with chronic hepatitis B (CHB) from 132 institutions.", "effective_dosage": "Not specified", "study_duration": "At least 16 weeks of ETV treatment for efficacy evaluation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.418548+00:00"}
{"study_id": 104146, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers sought to examine the efficacy and safety of PCSK9 inhibitors (alirocumab and evolocumab) in improving cardiovascular outcomes.", "results_summary": "The study found that PCSK9 inhibitors were associated with lower rates of myocardial infarction and were well tolerated, though no overall benefit was noted in all-cause or cardiovascular mortality.", "population_specificity": "45,539 patients with a mean age of 61.0\u00b12.8 years and mean baseline LDL cholesterol of 106\u00b122 mg/dL.", "effective_dosage": "Not mentioned", "study_duration": "Mean follow-up of 85.5 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:37.658987+00:00"}
{"study_id": 104145, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a codon-optimized AAV5 vector encoding a B-domain-deleted human factor VIII (AAV5-hFVIII-SQ) in men with severe hemophilia A, focusing on sustained normalization of factor VIII activity.", "results_summary": "The high-dose cohort showed sustained normalization of factor VIII activity in six of seven participants, with a significant reduction in bleeding events and cessation of factor VIII use by week 22. The primary adverse event was a mild elevation in serum alanine aminotransferase levels, with no serious safety concerns noted.", "population_specificity": "Nine men with severe hemophilia A.", "effective_dosage": "Low dose (1 participant), intermediate dose (1 participant), high dose (7 participants); specific amounts not detailed.", "study_duration": "Followed through 52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:38.462550+00:00"}
{"study_id": 104147, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study evaluated the efficacy and safety of buparlisib plus fulvestrant in patients with advanced breast cancer pretreated with endocrine therapy and mTOR inhibitors, not specifically Alanine.", "results_summary": "The study found that buparlisib plus fulvestrant significantly improved progression-free survival compared to placebo but had notable adverse effects, including elevated alanine aminotransferase. Alanine itself was not the focus of the study.", "population_specificity": "Postmenopausal women with hormone-receptor-positive, HER2-negative, locally advanced or metastatic breast cancer pretreated with endocrine therapy and mTOR inhibitors.", "effective_dosage": "Not applicable (Alanine not studied).", "study_duration": "Not applicable (Alanine not studied).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:39.570993+00:00"}
{"study_id": 104148, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the efficacy and safety of umbilical cord mesenchymal stem cells (UMSC) combined with traditional supportive therapy (TST) for treating liver cirrhosis (LC), including improvements in liver function markers like alanine aminotransferase.", "results_summary": "The combined therapy (UMSC plus TST) significantly improved liver function (e.g., reduced alanine aminotransferase) and clinical symptoms in LC patients without observed adverse events.", "population_specificity": "717 patients with liver cirrhosis.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:40.263410+00:00"}
{"study_id": 104149, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the quality of biological variation (BV) estimates in studies, including those related to Alanine, to ensure their reliability for clinical application.", "results_summary": "The study identified deficiencies in the quality of BV publications, with 9% receiving a D grade (unfit for clinical use). Meta-analysis provided combined CV estimates, but statistical analysis was often inadequate.", "population_specificity": "Not specified (general evaluation of BV studies)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:40.618959+00:00"}
{"study_id": 104151, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of low versus high-intensity training on biomarkers related to non-alcoholic fatty liver disease (NAFLD), including alanine aminotransferase, in adolescents with obesity.", "results_summary": "Both high and low-intensity training improved biomarkers related to NAFLD, with alanine aminotransferase showing a tendency to reduce in both groups, though the effect was more pronounced in the low-intensity group.", "population_specificity": "107 adolescents (15 \u00b1 1 years) with obesity (BMI = 34.7 \u00b1 4.1 kg/m\u00b2).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:44.439885+00:00"}
{"study_id": 104150, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the association between time-varying HBsAg serum levels and the risk of virological and clinical relapse in chronic hepatitis B patients after discontinuing nucleos(t)ide analog treatment.", "results_summary": "The study found that higher HBsAg serum levels were significantly associated with increased risk of virological and clinical relapse, with a dose-response relationship. Patients whose HBsAg levels dropped below 10 IU/mL had very low relapse rates.", "population_specificity": "Chronic hepatitis B patients who were serologically negative for HBeAg and viral DNA at the cessation of 3-year nucleos(t)ide analog treatment (n=140).", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 19.9 months (IQR 10.6-25.3 months)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:45.460902+00:00"}
{"study_id": 104154, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to identify predictors for a positive yield abdominal computed tomography (ACT) scan in pediatric abdominal trauma patients, including the role of elevated alanine aminotransferase (ALT) levels.", "results_summary": "Elevated ALT (>125 IU/L) was significantly associated with abnormal ACT scans (OR 46.28, P = 0.007), indicating its potential as a predictor for intra-abdominal injury in pediatric trauma patients.", "population_specificity": "Pediatric abdominal trauma patients (n=240) aged unspecified, treated at Children's Hospital at Westmead, New South Wales.", "effective_dosage": "Not applicable (ALT levels were measured, not administered).", "study_duration": "Retrospective analysis from January 2008 to June 2015.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:47.487368+00:00"}
{"study_id": 104152, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the efficacy and safety of pemafibrate (a novel selective peroxisome proliferator-activated receptor modulator) compared to fenofibrate in adults with dyslipidemia, focusing on triglyceride reduction and hepatic/renal safety.", "results_summary": "Pemafibrate significantly reduced triglyceride levels more effectively than fenofibrate (-46.2% and -45.9% vs. -39.7%) and demonstrated superior safety, with lower adverse drug reaction rates (2.7%-6.8% vs. 23.7%) and favorable effects on liver and kidney markers.", "population_specificity": "Adults with dyslipidemia (high triglycerides and low HDL cholesterol).", "effective_dosage": "Pemafibrate 0.2 mg/d or 0.4 mg/d; fenofibrate 106.6 mg/d.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:48.140165+00:00"}
{"study_id": 104155, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the influence of chronic hepatitis C (CHC) infection on the risk of anti-tuberculosis drug-induced liver injury (ATDILI), including the role of serum alanine aminotransferase (ALT) levels as a marker.", "results_summary": "The meta-analysis found that CHC infection significantly increases the risk of ATDILI, with higher odds ratios across different subgroups, including those with elevated ALT levels. The study concluded that regular liver tests are necessary for CHC carriers undergoing anti-TB therapy.", "population_specificity": "Patients undergoing anti-tuberculosis therapy, including those with and without chronic hepatitis C infection.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:48.456705+00:00"}
{"study_id": 104157, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to identify clinical markers, including alanine aminotransferase (ALT) levels, that predict CMV disease in bullous pemphigoid patients receiving corticosteroids.", "results_summary": "The study found that an increase in ALT levels 3-4 weeks after corticosteroid initiation is a useful predictive marker for CMV disease onset in bullous pemphigoid patients.", "population_specificity": "Bullous pemphigoid patients receiving corticosteroids.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:48.514615+00:00"}
{"study_id": 104153, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether alginate oligosaccharides (AOS) could improve therapeutic outcomes in degenerative lumbar disease (DLD) patients undergoing posterior lumbar intervertebral fusion with cages (PLIFC) by regulating miR-155 and reducing inflammation and oxidative stress.", "results_summary": "The study found that AOS (administered as ONAS) reduced infection rates and side effects compared to the control group, with lower serum miR-155 levels and improved oxidative stress and inflammatory markers. The treatment group also showed better clinical outcomes, including reduced complications and improved JOA scores.", "population_specificity": "96 DLD osteoporosis patients undergoing PLIFC surgery.", "effective_dosage": "100 mg ONAS daily (oral administration).", "study_duration": "1 month.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:48.691702+00:00"}
{"study_id": 104156, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety, tolerability, and antitumour activity of buparlisib in combination with trastuzumab in patients with HER2-positive advanced breast cancer, including those with progressive brain metastases.", "results_summary": "The study found that buparlisib plus trastuzumab had an acceptable safety profile but limited efficacy, with an overall response rate of 10%. In patients with brain metastases, some tumour shrinkage was observed, but efficacy remained modest.", "population_specificity": "Patients with trastuzumab-resistant, HER2-positive advanced breast cancer, including those with progressive brain metastases.", "effective_dosage": "Buparlisib 100 mg/day plus trastuzumab 2 mg/kg weekly; capecitabine was added in the Phase Ib portion.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:49.753207+00:00"}
{"study_id": 104158, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers investigated whether empagliflozin-mediated changes in remnant-like particle cholesterol (RLP-C) were associated with changes in insulin resistance, specifically focusing on the role of alanine aminotransferase in type 2 diabetes patients with insulin resistance.", "results_summary": "Empagliflozin significantly decreased RLP-C levels and improved insulin sensitivity, with changes in alanine aminotransferase and homeostatic model assessment of insulin resistance significantly associated with RLP-C reduction. The placebo group showed no significant changes except slight increases in liver transaminases.", "population_specificity": "Type 2 diabetes patients with insulin resistance (n = 109, 51 placebo, 58 empagliflozin).", "effective_dosage": "Not specified for alanine.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:53.770846+00:00"}
{"study_id": 104159, "supplement_id": 863, "safety_score": "20", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of duvelisib in patients with advanced hematologic malignancies, including its impact on alanine transaminase levels.", "results_summary": "The study found that duvelisib caused a significant increase in alanine transaminase (20% grade \u22653 adverse events), indicating potential liver toxicity. Clinical responses were observed across various hematologic malignancies, but safety concerns were notable.", "population_specificity": "Patients with advanced hematologic malignancies, including indolent non-Hodgkin lymphoma, chronic lymphocytic leukemia, and T-cell lymphoma.", "effective_dosage": "8 to 100 mg twice daily (MTD determined as 75 mg twice daily).", "study_duration": "Continuous treatment in the expansion phase (duration not explicitly stated).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:54.453652+00:00"}
{"study_id": 104160, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine if a quercetin-alanine bioconjugate could enhance cytotoxicity against cancer cell lines compared to quercetin alone.", "results_summary": "The quercetin-alanine bioconjugate showed a threefold increase in cytotoxicity for HeLa, A549, MCF-7, and LNCaP cells, with enhanced binding affinity to human estrogen receptor alpha and primary binding to Sudlow site I of serum albumin.", "population_specificity": "In vitro cancer cell lines (HeLa, A549, MCF-7, LNCaP, and six others).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:56.492695+00:00"}
{"study_id": 104161, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy and safety of Entecavir (ETV) from Dong-A ST versus ETV from BMS in treating chronic hepatitis B (CHB).", "results_summary": "The study found that ETV from Dong-A ST was noninferior to ETV from BMS in reducing HBV DNA levels, with no significant differences in efficacy or safety between the two groups. Secondary endpoints, including normalization of alanine aminotransferase (ALT) levels, also showed comparable results.", "population_specificity": "Treatment-na\u00efve patients with chronic hepatitis B (HBeAg-positive or negative).", "effective_dosage": "0.5 mg once daily.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:56.565847+00:00"}
{"study_id": 104163, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of adding pertuzumab to trastuzumab emtansine (T-DM1) \u00b1 taxane in HER2-positive breast cancer patients, not specifically Alanine.", "results_summary": "The study found that T-DM1 + pertuzumab \u00b1 taxane had common adverse events like fatigue, diarrhea, and increased ALT, but the addition of pertuzumab did not significantly improve objective response or clinical benefit rates.", "population_specificity": "Patients with HER2-positive locally advanced or metastatic breast cancer.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:57.061023+00:00"}
{"study_id": 104164, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 30, "study_goal": "The researchers aimed to report a case of telbivudine-induced severe polymyositis, lactic acidosis, and multiple organ failure, focusing on treatment outcomes.", "results_summary": "The study found that telbivudine use led to severe adverse effects, including elevated alanine aminotransferase and other markers of organ damage. Treatment with continuous renal replacement therapy, steroids, and rehabilitation improved the patient's condition.", "population_specificity": "A 30-year-old Chinese man with hepatitis B virus infection.", "effective_dosage": "600 mg of telbivudine daily.", "study_duration": "More than 11 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:57.528273+00:00"}
{"study_id": 104165, "supplement_id": 863, "safety_score": "30", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of LY2584702, a selective inhibitor of p70 S6 serine/threonine protein kinase-1, in healthy dyslipidemic volunteers, including its impact on lipid levels and potential adverse effects.", "results_summary": "LY2584702 reduced LDL cholesterol and triglycerides by up to 60% and 50%, respectively, without significantly altering HDL cholesterol. However, alanine aminotransferase elevations were observed in 2 subjects when combined with atorvastatin, suggesting potential hepatotoxicity risks.", "population_specificity": "Healthy dyslipidemic volunteers", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Atorvastatin (hepatotoxicity risk)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:58.264992+00:00"}
{"study_id": 104162, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to assess the association between elevated alanine aminotransaminase levels and poor outcomes in primary biliary cholangitis (PBC) patients undergoing ursodeoxycholic acid (UDCA) therapy.", "results_summary": "Elevated alanine aminotransaminase after 12 months of UDCA therapy was independently associated with poor outcomes (HR = 1.35, p = 0.04). The study did not focus on alanine as a supplement but rather as a biomarker in PBC progression.", "population_specificity": "501 PBC patients in Switzerland, predominantly women (84%), median age at diagnosis of 53 years.", "effective_dosage": "Not available", "study_duration": "Median follow-up of 5.4 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:58.501780+00:00"}
{"study_id": 104166, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to evaluate the safety and clinical feasibility of umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy in liver transplant patients with acute graft rejection, not specifically Alanine.", "results_summary": "The study assigned 27 liver allograft recipients with acute rejection into a UC-MSC infusion group or a control group, but results specific to Alanine were not mentioned.", "population_specificity": "Liver allograft recipients with acute rejection.", "effective_dosage": "Not mentioned (study involved UC-MSC infusion, not Alanine).", "study_duration": "Not mentioned (study involved a single UC-MSC infusion).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:01.681821+00:00"}
{"study_id": 104171, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate PASylation technology, which includes Alanine, as a method to enhance the pharmacokinetic properties of biopharmaceuticals by increasing their hydrodynamic volume.", "results_summary": "The study found that PASylation, involving Alanine, effectively prolonged the plasma half-life of biopharmaceuticals, making them suitable for production in various expression systems and demonstrating improved pharmacokinetic and pharmacodynamic properties in preclinical studies.", "population_specificity": "Preclinical studies (not specified if human or animal models).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:04.963454+00:00"}
{"study_id": 104168, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the risks and outcomes of treating HCV infection with ledipasvir and sofosbuvir in patients coinfected with HBV, not specifically studying Alanine.", "results_summary": "The study found that 100% of patients achieved sustained virologic response for HCV, but most experienced increases in HBV DNA levels without associated symptoms. The abstract does not mention Alanine or its effects.", "population_specificity": "111 patients with HCV and HBV coinfection (62% women, 16% with compensated cirrhosis) in Taiwan.", "effective_dosage": "Not mentioned (study focused on ledipasvir and sofosbuvir, not Alanine).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:04.965075+00:00"}
{"study_id": 104169, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy and safety of adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected EGFR-mutant stage II-IIIA NSCLC, not specifically to evaluate alanine.", "results_summary": "The study found that adjuvant gefitinib significantly improved disease-free survival compared to vinorelbine plus cisplatin in EGFR-mutant NSCLC patients. Raised alanine aminotransferase was noted as a grade 3 adverse event in the gefitinib group, but the study did not focus on alanine's effects.", "population_specificity": "Patients aged 18-75 with completely resected (R0), stage II-IIIA (N1-N2), EGFR-mutant NSCLC.", "effective_dosage": "Not applicable (study did not focus on alanine).", "study_duration": "24 months for gefitinib.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:06.067696+00:00"}
{"study_id": 104170, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to analyze associations between alanine aminotransferase (ALT), cytokeratin-18 (K-18), enhanced liver fibrosis (ELF) scores, and liver fat content in insulin-treated diabetes patients with NAFLD.", "results_summary": "Baseline K-18 and ELF scores were higher in T2D than T1D, with K-18 correlating with ALT in all populations and liver fat content in T2D. K-18 and ELF scores increased significantly in BIL-treated patients but not glargine-treated patients, with correlations between ALT and ELF score changes in BIL-treated groups.", "population_specificity": "Insulin-treated diabetes patients (type 1 and type 2) with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Up to 52 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:06.247084+00:00"}
{"study_id": 104167, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy and safety of a neoadjuvant regimen for HER2-positive breast cancer, replacing traditional chemotherapy with targeted treatment (trastuzumab emtansine plus pertuzumab) versus standard chemotherapy plus dual HER2-targeted therapy.", "results_summary": "The study found that traditional chemotherapy plus dual HER2-targeted therapy resulted in a higher pathological complete response rate (55.7%) compared to the targeted treatment group (44.4%). However, the targeted treatment group had fewer grade 3-4 adverse events (13% vs. 64%) and serious adverse events (5% vs. 29%).", "population_specificity": "Adults aged 18+ with HER2-positive stage II-III operable breast cancer (>2 cm tumor size), ECOG performance status 0-1, and baseline LVEF \u226555%.", "effective_dosage": "Trastuzumab emtansine (3.6 mg/kg) plus pertuzumab (840 mg loading dose, 420 mg maintenance doses) every 3 weeks for 6 cycles.", "study_duration": "6 cycles (every 3 weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:06.350646+00:00"}
{"study_id": 104173, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of deferasirox in reducing iron overload in pediatric patients with \u03b2-thalassemia major post-hematopoietic stem cell transplantation.", "results_summary": "Deferasirox significantly reduced serum ferritin levels and liver iron concentration, with manageable adverse events, primarily mild to moderate in severity. No deaths or serious adverse events were attributed to the treatment.", "population_specificity": "Pediatric patients (ages >2 to <18 years) with \u03b2-thalassemia major post-hematopoietic stem cell transplantation and evidence of iron overload.", "effective_dosage": "Initial dose of 10 mg/kg/day, up-titrated to a maximum of 20 mg/kg/day.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:06.975101+00:00"}
{"study_id": 104172, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the predictive role of the De Ritis ratio (DRR, alanine transaminase/aspartate transaminase) in outcomes after left ventricular assist device (LVAD) implantation.", "results_summary": "The study found that a higher DRR (>1.37) was an independent predictor of 30-day and 180-day mortality, postoperative acute kidney injury, and prolonged ventilation time. DRR showed high sensitivity and specificity for predicting 180-day mortality.", "population_specificity": "Patients undergoing LVAD implantation (mean age 59.9 years, 50% male).", "effective_dosage": "Not available", "study_duration": "Follow-up period of 180 days post-surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:07.201937+00:00"}
{"study_id": 104174, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to evaluate the safety, pharmacokinetics, and efficacy of buparlisib combined with capecitabine in patients with metastatic breast cancer, not Alanine.", "results_summary": "The study found that the combination of buparlisib and capecitabine was generally well-tolerated, with some patients showing prolonged responses. However, low rates of PIK3CA mutations and limited luminal tumor subtyping made predictive marker exploration impossible.", "population_specificity": "Patients with metastatic breast cancer.", "effective_dosage": "Buparlisib 50-100 mg once daily; capecitabine 1000-1250 mg/m\u00b2 twice daily.", "study_duration": "3 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:11.041651+00:00"}
{"study_id": 104177, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of CPAP treatment on liver-related outcomes, including alanine aminotransferase levels, in patients with OSA and NASH.", "results_summary": "The study found no significant changes in liver steatosis, fibrosis, or aminotransferase levels (including alanine aminotransferase) after CPAP treatment. The quality of evidence was rated as low to very low for these outcomes.", "population_specificity": "Patients with obstructive sleep apnea (OSA) and non-alcoholic steatohepatitis (NASH).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:15.225165+00:00"}
{"study_id": 104181, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare haematology and biochemistry parameters in healthy South African infants against local laboratory reference intervals to assess compatibility.", "results_summary": "The study found that haematology and biochemistry parameters in healthy South African infants frequently deviated from national laboratory reference intervals, with abnormalities consistent with subclinical hypochromic microcytic anaemia.", "population_specificity": "634 HIV-unexposed infants (316 male, 318 female), aged 3-6 months, living in a rural area of the Western Cape Province, South Africa.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:16.275718+00:00"}
{"study_id": 104179, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers investigated the etiology of acute viral hepatitis and compared clinical features of hepatitis E virus (HEV) infections with other acute viral hepatitis infections, including the role of elevated alanine aminotransferase levels as a diagnostic marker.", "results_summary": "The study found that acute HEV infection was associated with older age, male gender, and consumption of undercooked meat, with half of HEV cases involving underlying liver disease. Elevated alanine aminotransferase levels (>100 IU/L) were used as a diagnostic criterion, but no direct effects of alanine itself were studied.", "population_specificity": "2,357 patients diagnosed with acute hepatitis in Korea (2007\u20132016).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:16.871192+00:00"}
{"study_id": 104178, "supplement_id": 863, "safety_score": "100", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the therapeutic effect of a probiotic cocktail on non-alcoholic steatohepatitis (NASH), focusing on its impact on liver inflammation markers, including alanine aminotransferase (ALT).", "results_summary": "The probiotic cocktail significantly reduced serum ALT levels (>20%) and liver stiffness, indicating mitigation of inflammation, while also improving BMI and cholesterol levels. However, the reduction in GGT, a steatosis marker, was insignificant.", "population_specificity": "75 patients with NASH diagnosed by ultrasound and elevated GGT/ALT levels.", "effective_dosage": "Once daily for 12 weeks (exact dosage not specified).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:16.928580+00:00"}
{"study_id": 104176, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "To demonstrate the non-inferiority of tenofovir disoproxil fumarate (TDF) monotherapy compared to LAM+ADV combination therapy in maintaining virologic response in patients with chronic hepatitis B (CHB) and prior lamivudine (LAM) failure.", "results_summary": "TDF monotherapy was found to be non-inferior to LAM+ADV combination therapy in maintaining undetectable HBV-DNA levels and similar ALT values, with no significant adverse effects reported. The study also noted cost savings with TDF use.", "population_specificity": "Adult patients with HBeAg-negative CHB, prior LAM failure, on LAM+ADV for at least 6 months, without ADV resistance, and undetectable viral load at study start.", "effective_dosage": "Not specified for Alanine (study focused on TDF and LAM+ADV).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:17.104978+00:00"}
{"study_id": 104180, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review the endocrine manifestations of primary hyperoxaluria type 1 (PH1), including hypercalcemia, hypothyroidism, and hypogonadism, and present a case study.", "results_summary": "The study found that PH1 can lead to endocrine disturbances such as hypercalcemia mediated by 1,25-dihydroxyvitamin D and PTHrP, as well as hypothyroidism and hypogonadism due to calcium oxalate deposition. The case presented was the first to report PTHrP-mediated hypercalcemia and primary hypogonadism in a PH1 patient.", "population_specificity": "Patients with primary hyperoxaluria type 1 (PH1).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:17.399077+00:00"}
{"study_id": 104175, "supplement_id": 863, "safety_score": "65", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to explore optimal lonafarnib (LNF) regimens for treating hepatitis D virus (HDV) infection, including combinations with ritonavir (RTV) or pegylated interferon alfa (PEG-IFN\u03b1), and assess their impact on HDV RNA levels and safety.", "results_summary": "Higher LNF monotherapy doses reduced HDV viral load but increased gastrointestinal adverse events. Combining LNF with RTV or PEG-IFN\u03b1 improved antiviral responses with fewer side effects, and some patients achieved posttreatment HDV-RNA negativity.", "population_specificity": "Fifteen patients with HDV infection (divided into five groups of 3 patients each).", "effective_dosage": "Varied by group: LNF 200 mg BID, 300 mg BID, 100 mg TID, 100 mg BID + PEG-IFN\u03b1 180 \u03bcg QW, or 100 mg BID + RTV 100 mg QD.", "study_duration": "5 to 12 weeks, depending on the regimen.", "interactions": "RTV (a cytochrome P450 3A4 inhibitor) boosted LNF levels, and PEG-IFN\u03b1 enhanced antiviral effects when combined with LNF.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:18.533685+00:00"}
{"study_id": 104182, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the prognostic value of combining the neutrophil-to-lymphocyte ratio (NLR) and aspartate aminotransferase-to-alanine aminotransferase ratio (AAR) in patients with unresectable hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE).", "results_summary": "The study found that the NLR-AAR score was an independent marker of poor prognosis in HCC patients receiving TACE, with higher scores correlating with shorter median survival times. The NLR-AAR consistently showed greater discriminatory ability for survival prediction compared to NLR or AAR alone.", "population_specificity": "760 patients with newly diagnosed, unresectable HCC undergoing TACE.", "effective_dosage": "Not available", "study_duration": "Follow-up periods of 1, 3, and 5 years post-TACE.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:20.474557+00:00"}
{"study_id": 104183, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the effects of high-dose silymarin on clinical and biochemical status in chronic HCV-associated decompensated liver cirrhosis, including its impact on alanine transaminase levels.", "results_summary": "High-dose silymarin (1,050 mg/day) significantly reduced alanine transaminase and aspartate aminotransferase levels, improved albumin, bilirubin, and INR, and enhanced Child scores and quality of life, while the standard dose (420 mg/day) did not produce these effects. No serious adverse events were reported.", "population_specificity": "62 chronic HCV-decompensated cirrhotic patients.", "effective_dosage": "1,050 mg/day (high dose) and 420 mg/day (standard dose).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:24.549821+00:00"}
{"study_id": 104185, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers reviewed implantable drug-delivery systems, including N-stearoyl L-alanine methyl ester systems, for continuous drug delivery into the brain to treat various brain diseases.", "results_summary": "The abstract discusses the potential of implantable systems, including N-stearoyl L-alanine methyl ester, for sustained drug delivery in brain diseases, but does not provide specific efficacy data for alanine itself.", "population_specificity": "Not specified (review of implantable systems for brain diseases).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:24.631322+00:00"}
{"study_id": 104186, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the improvement of NAFLD after bariatric surgery, focusing on liver stiffness and fibrosis scores, including AST/ALT ratio, which involves alanine aminotransferase (ALT).", "results_summary": "The study found significant improvements in liver stiffness and fibrosis scores, including AST/ALT ratio, after bariatric surgery, with RYGB showing higher improvements than LSG. No correlation was detected between NAFLD improvement and weight loss.", "population_specificity": "100 patients scheduled for laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB).", "effective_dosage": "Not available", "study_duration": "Median follow-up of 12.5 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:25.358190+00:00"}
{"study_id": 104189, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the therapeutic potential of menstrual blood stem cells (MenSCs) and bone marrow-derived stem cells (BMSCs) in treating acute liver injury, including assessing the role of alanine aminotransferase as a biochemical marker.", "results_summary": "The study found that MenSCs significantly improved liver regeneration and reduced serum markers like alanine aminotransferase, with better outcomes than BMSCs. Hepatocyte progenitor-like cells derived from these stem cells showed superior effectiveness in treating acute liver injury.", "population_specificity": "Balb/C mice with induced liver injury.", "effective_dosage": "Not specified", "study_duration": "Follow-up until day 30 post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:25.440982+00:00"}
{"study_id": 104184, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the safety and efficacy of adjusted versus fixed standard doses of Ribavirin (RBV) in combination with PegIFNalfa-2a for treating chronic HCV genotype 4 in naive patients.", "results_summary": "The study found no significant difference in sustained virologic response (SVR) rates between adjusted and standard RBV doses, but higher anemia rates occurred with adjusted doses. Baseline alanine aminotransferase levels and other factors did not significantly affect SVR outcomes.", "population_specificity": "Chronic HCV genotype 4-naive patients (50.3% female, 76.5% with minimal-moderate fibrosis).", "effective_dosage": "Adjusted (ADJ) and fixed standard (STD) doses of RBV (specific amounts not detailed).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:25.504739+00:00"}
{"study_id": 104188, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to characterize hepatic findings in Joubert Syndrome (JS) and identify factors associated with probable portal hypertension, including the role of alanine aminotransferase (ALT) as a marker.", "results_summary": "Elevated alanine aminotransferase (ALT) levels were significantly higher in the probable portal hypertension group (92 vs 42 U/L, P = 0.004), suggesting liver involvement in JS patients with this condition. The study did not assess alanine as a supplement but rather as a biomarker of liver dysfunction.", "population_specificity": "100 individuals with Joubert Syndrome (JS) prospectively evaluated at the National Institutes of Health Clinical Center.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:25.772365+00:00"}
{"study_id": 104190, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to explore the role of nitrative stress in CBS activity deficiency and identify potential nitration sites on the CBS protein.", "results_summary": "The study found elevated nitrative stress levels in elderly people and aging rats, correlating with increased homocysteine levels; pretreatment with peroxynitrite was noted but results were not fully detailed.", "population_specificity": "Elderly people and natural aging/diet-induced hyperhomocysteinemia rats.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:26.366457+00:00"}
{"study_id": 104191, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the limitations of traditional biomarkers like serum alanine aminotransferase in assessing drug-induced liver injury (DILI) and explore the potential of in silico modeling (DILIsym) to improve risk assessment.", "results_summary": "The study highlights shortcomings of traditional biomarkers in detecting DILI risk, leading to potential false positives or missed risks. It proposes DILIsym as an innovative approach to better interpret biomarker data and more accurately assess liver safety in drug development.", "population_specificity": "Not specified (focus on biomarker assessment and modeling, not a specific human population).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:29.769432+00:00"}
{"study_id": 104195, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the use of liver stiffness measurement (Fibroscan) for monitoring liver fibrosis during antiviral therapy in chronic hepatitis B patients.", "results_summary": "The abstract does not mention Alanine or its effects, focusing instead on liver stiffness measurement for fibrosis monitoring in treated chronic hepatitis B.", "population_specificity": "Treated chronic hepatitis B patients", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:32.138137+00:00"}
{"study_id": 104192, "supplement_id": 863, "safety_score": "65", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety and efficacy of capecitabine (which involves alanine metabolism) combined with radiation therapy in improving progression-free survival in children with newly diagnosed DIPG.", "results_summary": "The study found that capecitabine and RT were well tolerated but did not improve outcomes, with earlier progression observed in the treatment group compared to historical controls. Increased alanine aminotransferase was among the common low-grade toxicities reported.", "population_specificity": "Children aged 3-17 years with newly diagnosed diffuse intrinsic pontine gliomas (DIPG).", "effective_dosage": "650 mg/m\u00b2 twice daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:33.442707+00:00"}
{"study_id": 104197, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to investigate the role of elevated alanine aminotransferase levels as a diagnostic marker in macrophage activation syndrome (MAS) associated with juvenile idiopathic arthritis (JIA).", "results_summary": "Elevated alanine aminotransferase levels were identified as one of the key laboratory findings in MAS associated with JIA, alongside other markers like hypertriglyceridemia, anemia, and hyperferritinemia. The study did not evaluate alanine's therapeutic effects but highlighted its diagnostic relevance in MAS.", "population_specificity": "Children and adolescents with juvenile idiopathic arthritis (JIA) and macrophage activation syndrome (MAS).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:33.736478+00:00"}
{"study_id": 104196, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the antiviral efficacy of NVR3-778, alone or in combination with peg-IFN or entecavir, and its effects on innate and ER stress responses in HBV-infected humanized mice.", "results_summary": "NVR3-778 significantly reduced serum HBV DNA and RNA levels, with the greatest reduction observed when combined with peg-IFN. It did not significantly affect alanine aminotransferase levels, ER stress, or IFN-stimulated genes.", "population_specificity": "uPA/SCID mice with humanized livers and stable HBV genotype C infection.", "effective_dosage": "Not specified in the abstract.", "study_duration": "6 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:33.976204+00:00"}
{"study_id": 104193, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 65, "study_goal": "The researchers aimed to explore the association between obesity and hypertension by analyzing correlations between clinical laboratory data, including alanine aminotransferase (ALT), and phenotypic measures in specific Chinese adult groups.", "results_summary": "The study found that serum levels of alanine aminotransferase (ALT) were statistically significantly different between the four groups and positively correlated with waist circumference (WC) and body mass index (BMI).", "population_specificity": "153 Chinese adults (34 women, 119 men) aged 21-69, divided into four groups: newly diagnosed untreated just-obesity, obesity-hypertension, just-hypertension, and normal healthy.", "effective_dosage": "Not available", "study_duration": "Cross-sectional study conducted from September 2012 to July 2014 (no specific intervention duration).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:34.003970+00:00"}
{"study_id": 104198, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare the therapeutic outcomes of intraluminal brachytherapy (ILBT) versus stent alone in patients with malignant obstructive jaundice (MOJ), including effects on alanine aminotransferase (ALT) levels.", "results_summary": "The study found no significant difference in post-treatment ALT levels between ILBT and stent-alone groups, suggesting comparable effects on ALT. ILBT showed better outcomes in stent occlusion and mean survival but no advantage in ALT reduction.", "population_specificity": "641 participants with malignant obstructive jaundice (MOJ).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:34.545963+00:00"}
{"study_id": 104194, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to assess the safety and maximum tolerated dose of a vinflunine/pemetrexed combination in metastatic urothelial cell carcinoma patients, including monitoring for hepatobiliary toxicity involving alanine aminotransaminase.", "results_summary": "The study observed dose-limiting toxicities, including grade 3 hepatobiliary toxicity with elevated alanine aminotransaminase in one patient. The combination was poorly tolerated, and the trial was halted for safety reasons.", "population_specificity": "Metastatic urothelial cell carcinoma patients (mean age 66 years, prior GC-cycle exposure).", "effective_dosage": "Pemetrexed starting at 400 mg/m\u00b2, vinflunine at 280 mg/m\u00b2 (21-day cycle).", "study_duration": "Three cycles (21-day cycles).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:34.609231+00:00"}
{"study_id": 104199, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to review the role of protein misfolding, particularly involving alanine/glyoxylate aminotransferase (AGT), in primary hyperoxalurias and explore potential therapeutic strategies.", "results_summary": "The study found that pathogenic mutations in AGT, GRHPR, and HOGA1 lead to protein misfolding, causing enzymatic deficits and disease manifestations like calcium oxalate deposition in kidneys. Molecules improving folding yield of these enzymes could offer new therapeutic approaches.", "population_specificity": "Patients with primary hyperoxalurias (Types I, II, and III).", "effective_dosage": "Not available", "study_duration": "Not applicable (review study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:38.742104+00:00"}
{"study_id": 104203, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not investigate Alanine; it evaluates the efficacy and safety of tofacitinib in patients with psoriatic arthritis.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with active psoriatic arthritis who had an inadequate response to TNF inhibitors.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:41.074972+00:00"}
{"study_id": 104200, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety, tolerability, pharmacokinetics, and efficacy of AZD3759 (not Alanine) in patients with EGFR-mutant NSCLC with brain and leptomeningeal metastases.", "results_summary": "AZD3759 showed a tolerable safety profile at 200 mg twice daily, with common adverse events being skin and gastrointestinal disorders. The drug demonstrated promising clinical activity and good blood-brain barrier penetration.", "population_specificity": "Patients with advanced-stage, EGFR-mutant NSCLC and brain or leptomeningeal metastases.", "effective_dosage": "50 mg, 100 mg, 200 mg, 300 mg, or 500 mg twice daily (200 mg and 300 mg selected for expansion).", "study_duration": "From Nov 18, 2014, to data cutoff on Dec 12, 2016 (variable per patient).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:41.819601+00:00"}
{"study_id": 104206, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study evaluated the safety and efficacy of cabozantinib in patients with recurrent or progressive glioblastoma, not specifically Alanine.", "results_summary": "The study reported increased alanine aminotransferase (37.1%) as a common adverse event, but did not assess Alanine's effects or safety.", "population_specificity": "Patients with recurrent or progressive glioblastoma who had received prior antiangiogenic therapy.", "effective_dosage": "Not applicable (study focused on cabozantinib, not Alanine).", "study_duration": "Until disease progression or unacceptable toxicity.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:42.419492+00:00"}
{"study_id": 104201, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to explore the clinical efficacy and safety of the MESA regimen (including pegaspargase) for ENKTL and identify novel serum biomarkers, including alanine, as prognostic indicators.", "results_summary": "Alanine was identified as part of the AspM score, which predicted superior survival in ENKTL patients. The AspM score, including alanine, was validated as an independent prognostic factor.", "population_specificity": "Newly diagnosed, stage IE-IIE extranodal natural-killer/T-cell lymphoma, nasal-type (ENKTL) patients.", "effective_dosage": "Not specified for alanine (part of metabolic profiling).", "study_duration": "Four cycles of MESA sandwiched with radiotherapy (exact duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.314504+00:00"}
{"study_id": 104205, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were evaluating the long-term safety and efficacy of nivolumab plus ipilimumab combination therapy in patients with advanced melanoma, not specifically studying alanine.", "results_summary": "The study reported a 3-year overall survival rate of 63% and an objective response rate of 42%, with common grade 3/4 adverse events including increased alanine aminotransferase (12%).", "population_specificity": "Patients with previously treated or untreated advanced melanoma.", "effective_dosage": "Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks for four doses, followed by nivolumab 3 mg/kg once every 2 weeks.", "study_duration": "Follow-up ranged from 30.3 to 55.0 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:43.736515+00:00"}
{"study_id": 104202, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the efficacy and safety of mycophenolate mofetil as rescue therapy for patients with autoimmune hepatitis (AIH) who had suboptimal responses or intolerance to standard therapy, including monitoring alanine and aspartate transferase levels.", "results_summary": "The study found that 60% of patients achieved biochemical remission (normalized alanine and aspartate transferase levels) after a median of 12 weeks of mycophenolate mofetil therapy. Patients with cirrhosis had lower remission rates (47%) compared to those without (6%), and adverse events led to discontinuation in 9.2% of cases.", "population_specificity": "Patients with autoimmune hepatitis (AIH) who failed or were intolerant to standard corticosteroid therapy, with or without azathioprine.", "effective_dosage": "Not specified", "study_duration": "Median 12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:44.276633+00:00"}
{"study_id": 104204, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of Sofosbuvir plus RBV versus peg-IFN plus RBV on liver function, fibrosis, and hepatocellular carcinoma markers, including alanine aminotransferase (ALT) levels.", "results_summary": "Sofosbuvir plus RBV significantly reduced ALT levels and improved liver fibrosis markers (FIB-4, APRI, BMP-7, CTGF) compared to peg-IFN plus RBV, which showed no significant change in fibrosis markers. Platelet counts increased in the Sofosbuvir group but decreased in the peg-IFN group.", "population_specificity": "Patients with hepatitis C (n = 21 for Sofosbuvir plus RBV, n = 24 for peg-IFN plus RBV).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Duration until end of treatment (EOT), exact length not specified.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:44.571754+00:00"}
{"study_id": 104207, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether antiviral treatment reduces the risk of liver disease progression (HCC and cirrhosis) in patients with HBeAg-positive chronic HBV infection and high HBV load, despite normal ALT levels.", "results_summary": "Antiviral therapy significantly reduced the risk of HCC (HR, 0.234) and cirrhosis (HR, 0.235) compared to the control group, with consistent results after propensity score matching and inverse probability weighting.", "population_specificity": "Patients with HBeAg-positive chronic HBV infection, HBV DNA >20000 IU/mL, ALT <40 IU/L, and no cirrhosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:47.194627+00:00"}
{"study_id": 104208, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it focuses on Obeticholic acid (OCA) for primary biliary cholangitis.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with primary biliary cholangitis intolerant to ursodeoxycholic acid.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:48.331273+00:00"}
{"study_id": 104209, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine the role of cell death, including markers like alanine aminotransferase, in patients with cirrhosis and acute decompensation (AD) or acute on chronic liver failure (ACLF).", "results_summary": "The study found that cell death markers, including alanine aminotransferase, correlated with disease severity in AD and ACLF, with nonapoptotic cell death predominating in more severe cases. The inclusion of these markers improved prediction of progression from AD to ACLF.", "population_specificity": "Patients with cirrhosis and acute decompensation (AD) or acute on chronic liver failure (ACLF), healthy volunteers, and stable cirrhosis patients.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:50.468680+00:00"}
{"study_id": 104212, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to determine the maximum-tolerated dose of a triplet combination (dasatinib, erlotinib, and gemcitabine) for pancreatic adenocarcinoma treatment, not specifically focused on Alanine.", "results_summary": "The abstract does not mention any findings related to Alanine.", "population_specificity": "Patients with pancreatic adenocarcinoma.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Not mentioned for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:50.645304+00:00"}
{"study_id": 104211, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of hypothermic oxygenated machine perfusion (HOPE) on extended criteria donor liver allografts, with alanine aminotransferase (ALT) levels as a primary endpoint to assess ischemia-reperfusion injury.", "results_summary": "The study compared HOPE-treated liver grafts with conventional cold storage, measuring peak and \u0394 peak ALT within 7 days post-transplant, along with secondary endpoints like AST, bilirubin, and graft survival. Results were pending at the time of the abstract.", "population_specificity": "Patients receiving orthotopic liver transplantation (OLT) with extended criteria donor allografts from donation after brain death (DBD).", "effective_dosage": "Not specified (HOPE administered for 1-2 hours via portal vein).", "study_duration": "1-2 hours of HOPE before implantation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:52.697595+00:00"}
{"study_id": 104213, "supplement_id": 863, "safety_score": "40", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of orantinib combined with cTACE in patients with unresectable hepatocellular carcinoma, including monitoring adverse effects like elevated alanine aminotransferase levels.", "results_summary": "The study found no improvement in overall survival with orantinib compared to placebo. Elevated alanine aminotransferase was a frequent adverse event, occurring in 34% of the orantinib group versus 30% in the placebo group.", "population_specificity": "Patients with unresectable hepatocellular carcinoma, no extra-hepatic tumor spread, and Child-Pugh score of 6 or less.", "effective_dosage": "200 mg twice per day.", "study_duration": "Until TACE failure or unacceptable toxicity (median follow-up 17.3 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:53.117974+00:00"}
{"study_id": 104210, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to compare the therapeutic effects of fenofibrate and pioglitazone on NAFLD, including their impact on alanine aminotransferase levels.", "results_summary": "The study found that both fenofibrate and pioglitazone significantly reduced alanine aminotransferase levels, along with other markers like aspartate transaminase, blood pressure, and BMI in NAFLD patients. The results suggest beneficial effects of these treatments on fatty liver.", "population_specificity": "Patients with NAFLD and alanine aminotransferase levels 1-1.5 times the normal range, with a BMI of 25-35.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:53.123482+00:00"}
{"study_id": 104214, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the use of alanine absolute dosimetry in measuring absorbed dose during HDR and PDR brachytherapy for gynaecological tumours.", "results_summary": "The study demonstrated that alanine dosimetry effectively measured absorbed dose at clinically relevant distances (20 mm and 50 mm) from the brachytherapy source, with measurements taken in 47 UK centres. The method showed consistency across multiple centres and source types (HDR and PDR).", "population_specificity": "UK centres participating in the INTERLACE trial and non-INTERLACE brachytherapy centres treating gynaecological tumours.", "effective_dosage": "10 Gy at 20 mm from the source (simulated line source).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:53.535385+00:00"}
{"study_id": 104215, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of cyclic parenteral nutrition (cPN) in treating liver dysfunction (LD) associated with parenteral nutrition (PN).", "results_summary": "cPN improved hepatic function parameters (AST, GGT, TB, and ALT) in patients with PN-associated LD, with statistically significant improvements in AST, GGT, and TB. The study concluded that cPN is effective in reversing PN-associated LD.", "population_specificity": "Inpatients aged \u226518 years with PN-associated liver dysfunction at Costa del Sol Hospital, Spain (2013-2014).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:55.575921+00:00"}
{"study_id": 104216, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of carbamazepine (CBZ) and valproate (VPA) monotherapy on serum levels of alanine aminotransferase (ALT) and other liver enzymes in children with epilepsy.", "results_summary": "The study found that ALT levels were elevated in 9.4% of CBZ-treated patients and 19.15% of VPA-treated patients after 12 months, with statistically significant differences. GGT levels were elevated more frequently in CBZ-treated patients (34%) compared to VPA-treated patients (14.9%).", "population_specificity": "100 pediatric patients (ages 1-18 years) with epilepsy, treated with CBZ or VPA as initial monotherapy.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:57.920232+00:00"}
{"study_id": 104220, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it compares the efficacy and safety of dacomitinib versus gefitinib in treating EGFR-mutation-positive NSCLC.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC).", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:59.688526+00:00"}
{"study_id": 104219, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates the combination of doxorubicin and PM01183 in relapsed small-cell lung cancer.", "results_summary": "The study does not report findings specific to Alanine.", "population_specificity": "Patients with advanced solid tumors, including relapsed small-cell lung cancer.", "effective_dosage": "Not applicable (Alanine not studied).", "study_duration": "Not applicable (Alanine not studied).", "interactions": "None mentioned (Alanine not studied).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:00.229902+00:00"}
{"study_id": 104217, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Alanine-glyoxylate aminotransferase 2 (AGXT2) in cardiovascular and renal diseases by examining its impact on ADMA and SDMA metabolism.", "results_summary": "The study suggests that AGXT2 deficiency may influence cardiovascular and renal disease progression by affecting ADMA/SDMA levels, but it does not provide direct evidence of Alanine's effects. The review summarizes AGXT2's functions and clinical associations but does not present new experimental results on Alanine.", "population_specificity": "Not specified (review of existing literature).", "effective_dosage": "Not available.", "study_duration": "Not applicable (review study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:00.723750+00:00"}
{"study_id": 104222, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to analyze liver disease in HIV-infected children and adolescents, focusing on markers like alanine aminotransferase (ALT) to assess liver abnormalities.", "results_summary": "The study found that liver disease, indicated by elevated ALT and other markers, was more prevalent in HIV-infected patients with HBV or HCV coinfection (88%) compared to those without (18%). Coinfection and detectable HIV viral load were independently associated with higher liver fibrosis scores.", "population_specificity": "HIV-infected children and adolescents (mean age 14.0 \u00b1 5.1 years) receiving combination antiretroviral therapy (cART).", "effective_dosage": "Not specified", "study_duration": "Mean duration of cART was 11.5 \u00b1 4.7 years.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:02.467446+00:00"}
{"study_id": 104221, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to estimate the magnitude of hepatopathy in malaria and study its associated clinical features, complications, and outcomes.", "results_summary": "Hepatopathy was observed in 22% of acute malaria cases, with significant associations between hepatopathy and bleeding events, thrombocytopenia, elevated transaminases (including alanine transaminases), and increased mortality. Hepatopathy was also significantly linked to renal dysfunction.", "population_specificity": "Patients with acute malaria (ages 2-96 years, 63.2% male) due to Plasmodium vivax, P. falciparum, or co-infection.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:02.821901+00:00"}
{"study_id": 104218, "supplement_id": 863, "safety_score": "65", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety and efficacy of REP 2139 and pegylated interferon alfa-2a in patients with chronic HBV and HDV co-infection, focusing on functional control of the infections and normalization of serum aminotransferases.", "results_summary": "The study found that combined therapy was safe and well-tolerated, with significant reductions in HBsAg levels, suppression of HBV DNA, and HDV RNA negativity in a high proportion of patients, maintained at 1-year follow-up. Elevated alanine and aspartate aminotransferase levels were noted but were restricted to patients with low HBsAg levels before interferon introduction.", "population_specificity": "Treatment-naive, HBeAg-negative, anti-HDAg-positive, HDV RNA-positive patients aged 18-55 with chronic HBV and HDV co-infection and serum HBsAg >1000 IU/mL.", "effective_dosage": "500 mg intravenous REP 2139 weekly for 15 weeks, then 250 mg REP 2139 + 180 \u03bcg pegylated interferon alfa-2a weekly for 15 weeks, followed by 180 \u03bcg interferon weekly for 33 weeks.", "study_duration": "63 weeks (15 + 15 + 33 weeks).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:03.137194+00:00"}
{"study_id": 104223, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to compare the long-term efficacy and safety of entecavir (ETV) and lamivudine (LAM) in Korean patients with HBeAg-negative chronic hepatitis B (CHB), focusing on virologic response and alanine aminotransferase (ALT) normalization.", "results_summary": "ETV demonstrated significantly higher virologic response rates (95.0% vs. 47.6%) and ALT normalization (87.5% vs. 51.6%) compared to LAM over 240 weeks, with minimal resistance and no serious adverse events linked to the medications.", "population_specificity": "Korean patients (>16 years old) with HBeAg-negative chronic hepatitis B.", "effective_dosage": "ETV 0.5 mg/day or LAM 100 mg/day.", "study_duration": "240 weeks (96-week double-blind phase followed by open-label treatment).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:05.380237+00:00"}
{"study_id": 104224, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine if prophylactic dexamethasone reduces postembolization syndrome (PES) after chemoembolization for hepatocellular carcinoma (HCC), including effects on alanine aminotransferase levels.", "results_summary": "Dexamethasone significantly reduced PES incidence (78.0% vs. 97.5%) and lowered antiemetic/analgesic use, but hospitalization times were similar. Alanine aminotransferase elevation was evaluated but specific results for alanine were not highlighted.", "population_specificity": "88 patients with intermediate-stage HCC.", "effective_dosage": "12 mg intravenous dexamethasone (single dose).", "study_duration": "Single administration before chemoembolization.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:07.215732+00:00"}
{"study_id": 104225, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the incidence, determinants, and outcomes of hepatitis B virus (HBV) flare, measured by alanine aminotransferase (ALT) levels, in pregnant HBV-infected women.", "results_summary": "The study found that HBV flare occurred in 14% of pregnancies during pregnancy and 16% post-delivery, with jaundice developing in 12% and hepatic decompensation in 2%. Positive HBeAg was identified as the main risk factor for HBV flare.", "population_specificity": "Pregnant hepatitis B surface antigen-positive women, predominantly African, from Southeastern Pennsylvania (2006-2015).", "effective_dosage": "Not mentioned", "study_duration": "Pregnancy and up to 6 months post-delivery", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:08.361390+00:00"}
{"study_id": 104226, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to identify variables affecting phenobarbital pharmacokinetics and evaluate optimal dosage regimens in term asphyxiated neonates, not specifically focused on Alanine.", "results_summary": "The study found phenobarbital volume of distribution was associated with body weight, length, and body surface area, but clearance was not linked to any explored features, including alanine aminotransferase. Optimal dosing was determined as 15 mg/kg loading dose and 3 mg/kg daily maintenance dose.", "population_specificity": "Term asphyxiated neonates during the first week of life.", "effective_dosage": "15 mg/kg loading dose, 3 mg/kg daily maintenance dose.", "study_duration": "First week of life.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:08.646497+00:00"}
{"study_id": 104227, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to evaluate changes in alanine levels in cerebrospinal fluid (CSF) as part of a broader meta-analysis comparing synaptic and metabolic markers between Alzheimer's disease (AD) patients and controls.", "results_summary": "The study found a non-significant increase in alanine levels in AD patients compared to controls (RoM 1.10, 95% CI 0.98-1.23, p=0.09), suggesting a marginal but not statistically significant association with AD.", "population_specificity": "605 Alzheimer's disease patients and 585 controls.", "effective_dosage": "Not available", "study_duration": "Not applicable (meta-analysis of existing studies)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:09.182211+00:00"}
{"study_id": 104230, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to characterize the exposure-response relationship of isavuconazole for efficacy and safety in patients with invasive aspergillosis and other filamentous fungal infections.", "results_summary": "The study analyzed exposure parameters against efficacy and safety endpoints but found no statistically significant relationship for the endpoints evaluated, including alanine aminotransferase abnormalities.", "population_specificity": "Patients with invasive aspergillosis and infections by other filamentous fungi (n=231).", "effective_dosage": "Clinical dosing regimen (specific dosage not mentioned).", "study_duration": "Follow-up through day 42.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:11.344263+00:00"}
{"study_id": 104228, "supplement_id": 863, "safety_score": "90", "efficacy_score": 80, "quality_score": 85, "study_goal": "To evaluate the efficacy and safety of HL tablet (containing Alanine) in reducing hepatic fat content (HFC) and improving metabolic parameters in patients with NAFLD.", "results_summary": "The high-dose HL tablet significantly reduced HFC after 12 weeks, with no negative effects on lipid profiles, BMI, or adverse effects reported. The low-dose group did not show significant changes in HFC.", "population_specificity": "74 patients with NAFLD diagnosed by ultrasonography.", "effective_dosage": "High dose (400 mg/day), low dose (133.4 mg/day), and placebo.", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:11.752336+00:00"}
{"study_id": 104229, "supplement_id": 863, "safety_score": "75", "efficacy_score": 60, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CPT (a novel antitumor drug candidate) in patients with relapsed or refractory multiple myeloma (RRMM) and identify the recommended dose for phase 2 studies.", "results_summary": "CPT was safe and well-tolerated, with common adverse events including liver enzyme elevations and hematological abnormalities. The overall response rate was 18.5%, with higher doses showing better responses.", "population_specificity": "Patients with relapsed or refractory multiple myeloma (RRMM).", "effective_dosage": "5, 6.5, 8, 10, and 15 mg/kg, administered once daily for 5 consecutive days per 21-day cycle.", "study_duration": "Treatment cycles lasted 21 days, with multiple cycles administered as needed.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:12.868342+00:00"}
{"study_id": 104232, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it evaluates rucaparib's efficacy and safety in patients with platinum-sensitive ovarian cancer.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:13.428584+00:00"}
{"study_id": 104231, "supplement_id": 863, "safety_score": "40", "efficacy_score": 64, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the antitumour activity and safety profile of dabrafenib plus trametinib in patients with previously untreated BRAF-mutated metastatic melanoma, with a focus on adverse events including alanine aminotransferase increase.", "results_summary": "The study found that 64% of patients achieved an overall response, with 6% complete and 58% partial responses. Adverse events were common, including grade 3 or 4 alanine aminotransferase increase in 11% of patients and serious adverse events in 14%.", "population_specificity": "Adults (\u226518 years) with previously untreated metastatic BRAF-mutated melanoma.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Median follow-up was 15.9 months (IQR 7.8-22.0).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:15.132549+00:00"}
{"study_id": 104233, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were attempting to evaluate the role of rifaximin as a primary prevention of hepatorenal syndrome (HRS) in patients with liver cirrhosis and ascites.", "results_summary": "The study found that rifaximin significantly reduced the progression of blood urea nitrogen and serum creatinine levels compared to the control group, and HRS developed less frequently in the rifaximin group (5% vs. 22.5%).", "population_specificity": "Patients with liver cirrhosis and ascites (n=80).", "effective_dosage": "550 mg twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:16.715633+00:00"}
{"study_id": 104234, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine whether vitamin D supplementation affects alanine aminotransferase (ALT) levels and other hepatic enzymes in individuals without liver disease.", "results_summary": "The study found no significant relationship between 25(OH)D concentrations and ALT levels, and vitamin D supplementation did not affect ALT or other hepatic enzymes in vitamin D-deficient, overweight, or obese individuals.", "population_specificity": "Drug-na\u00efve individuals with no history of liver disease, including a subgroup of 54 vitamin D-deficient overweight or obese individuals.", "effective_dosage": "100,000 IU loading dose of cholecalciferol followed by 4,000 IU daily.", "study_duration": "16 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:17.051946+00:00"}
{"study_id": 104235, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of propofol medium-long chain lipid emulsion on cognitive function and treatment outcomes in patients with hepatic encephalopathy undergoing hemofiltration.", "results_summary": "The study found that propofol medium-long chain lipid emulsion significantly reduced blood ammonia, \u03b2-endorphin, total bilirubin, ALT, and GGT levels, and improved cognitive function (MMSE scores) in hepatic encephalopathy patients compared to controls.", "population_specificity": "87 patients diagnosed with hepatic encephalopathy undergoing hemofiltration treatment.", "effective_dosage": "Initial intravenous dose of 100 mg, followed by micro-infusion pump at 0.5\u20134 mg/kg/h.", "study_duration": "24 hours of sedation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:18.614486+00:00"}
{"study_id": 104236, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the diagnostic performance of the globulin-platelet (GP) model for liver fibrosis and cirrhosis in chronic hepatitis B (CHB) patients with high HBV DNA and mildly elevated alanine transaminase (ALT) levels.", "results_summary": "The GP model showed lower accuracy than APRI but equivalent to FIB-4 for predicting significant fibrosis, equivalent to both for severe fibrosis, and higher accuracy for diagnosing cirrhosis. The clinical application of the GP model may reduce the need for liver biopsy in CHB patients.", "population_specificity": "316 CHB patients with HBV DNA \u2265 4 log10 copies/mL and 40 IU/L < ALT \u2264 80 IU/L.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:21.267025+00:00"}
{"study_id": 104239, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy and side effects of methotrexate and leflunomide as first-line DMARDs in rheumatoid arthritis patients, not specifically focused on Alanine.", "results_summary": "The study found no significant difference in efficacy between leflunomide and methotrexate for most outcomes, except for a greater reduction in swollen joint count with methotrexate. Leflunomide was associated with more liver enzyme increases, while methotrexate had more GI complaints.", "population_specificity": "Patients with rheumatoid arthritis (RA)", "effective_dosage": "Not specified for Alanine", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:21.491460+00:00"}
{"study_id": 104238, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety, optimal dosing, and activity of TargomiRs (not Alanine) in patients with malignant pleural mesothelioma.", "results_summary": "The study found an acceptable safety profile and early signs of activity for TargomiRs, supporting further research in combination with chemotherapy or immune checkpoint inhibitors. Five dose-limiting toxicities were noted, including infusion-related inflammatory symptoms and coronary ischemia.", "population_specificity": "Adults (\u226518 years) with confirmed malignant pleural mesothelioma, measurable disease, progression after chemotherapy, and adequate organ function.", "effective_dosage": "Five dose cohorts with intravenous infusion once or twice a week (3 days apart).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:22.579276+00:00"}
{"study_id": 104237, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the real-world efficacy of Entecavir (ETV) in chronic hepatitis B (CHB) patients, focusing on virological response, HBsAg loss, and HBeAg clearance/seroconversion.", "results_summary": "ETV effectively suppressed HBV DNA, with cumulative virological response rates increasing to 94.4% at 60 months, but HBsAg loss did not occur, and HBeAg clearance rates were lower than in clinical trials. Partial virological response (PVR) was associated with HBeAg clearance and cirrhosis.", "population_specificity": "Treatment-na\u00efve CHB patients (n=233, 175 male, mean age 43 years, 135 HBeAg positive).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Mean follow-up of 28 months (treatment duration at least 12 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:22.716634+00:00"}
{"study_id": 104241, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the outcomes of preoperative endoscopic nasobiliary drainage (ENBD) and endoscopic retrograde biliary drainage (ERBD) in patients with malignant distal biliary obstruction prior to pancreaticoduodenectomy (PD).", "results_summary": "ENBD was found to be an optimal method for patients with malignant distal biliary obstruction prior to PD, while ERBD was superior in patient tolerance and biliary drainage effect but associated with higher risks of procedure-related cholangitis and deep abdominal infection post-PD.", "population_specificity": "153 patients with malignant distal biliary obstruction undergoing preoperative endoscopic biliary drainage prior to pancreaticoduodenectomy.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:25.907670+00:00"}
{"study_id": 104242, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to evaluate noninvasive blood markers, including alanine aminotransferase, for differentiating nonalcoholic steatohepatitis (NASH) from simple steatosis (SS).", "results_summary": "The study found that no blood marker, including alanine aminotransferase, achieved high pooled sensitivity and specificity (\u226580%) for differentiating NASH from SS, though some scoring systems in single studies showed promise.", "population_specificity": "Human adults with nonalcoholic fatty liver disease.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:26.038276+00:00"}
{"study_id": 104240, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to compare the feasibility, toxicity, and efficacy of two different S-1 administration schedules (including alanine transaminase effects) in adjuvant chemotherapy for non-small cell lung cancer patients.", "results_summary": "The study found that the conventional S-1 schedule (arm A) had higher completion rates and dose intensity compared to the shorter schedule (arm B), with no significant difference in 3-year disease-free survival. Grade 1-3 elevations in alanine transaminase and other liver enzymes were more frequent in arm A, but overall toxicity differences were not significant.", "population_specificity": "Surgically treated pathological stage IB-IIIA non-small cell lung cancer patients.", "effective_dosage": "Arm A: 4 weeks of oral S-1 followed by a 2-week rest, repeated over 12 months; Arm B: 2 weeks of S-1 followed by a 1-week rest, repeated over 12 months.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:26.451018+00:00"}
{"study_id": 104243, "supplement_id": 863, "safety_score": "60", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of ADI-PEG 20 (a pegylated arginine deiminase) in combination with gemcitabine and nab-paclitaxel for treating metastatic pancreatic cancer, including its effects on ASS1-deficient and -proficient tumors.", "results_summary": "The study found that ADI-PEG 20 was well tolerated in combination therapy, with common adverse events including hematologic toxicities. Activity was observed in both previously treated and untreated patients, regardless of ASS1 status.", "population_specificity": "Patients with metastatic pancreatic cancer, Eastern Cooperative Oncology Group performance status 0-1, and limited prior treatment.", "effective_dosage": "36 mg/m\u00b2 weekly (RP2D for ADI-PEG 20).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:28.372428+00:00"}
{"study_id": 104244, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the prevalence and early changes of abnormal liver function tests (LFTs), particularly alanine aminotransferase (ALT), and their impact on 90-day mortality in patients with cardiogenic shock.", "results_summary": "Baseline ALT was abnormal in 58% of patients, more frequently in nonsurvivors. A >20% increase in ALT within 24 hours was independently associated with a more than 2-fold increase in 90-day mortality.", "population_specificity": "178 patients with cardiogenic shock.", "effective_dosage": "Not available", "study_duration": "Measurements taken at 0, 12, and 24 hours.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:29.501891+00:00"}
{"study_id": 104246, "supplement_id": 863, "safety_score": "30", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the anti-cholestatic effects and safety of seladelpar, a PPAR-\u03b4 agonist, in patients with primary biliary cholangitis who had an inadequate response to ursodeoxycholic acid.", "results_summary": "Seladelpar significantly reduced alkaline phosphatase levels compared to placebo, with mean changes of -53% (50 mg) and -63% (200 mg), but the study was terminated early due to grade 3 alanine aminotransferase increases in three patients. Adverse events included pruritus, nausea, and muscle spasms.", "population_specificity": "Patients with primary biliary cholangitis and alkaline phosphatase \u22651.67 times the upper limit of normal despite ursodeoxycholic acid treatment.", "effective_dosage": "50 mg/day and 200 mg/day", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:31.455103+00:00"}
{"study_id": 104245, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 99, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy and safety of 12 weeks of coformulated glecaprevir and pibrentasvir in patients with hepatitis C virus (HCV) infection and compensated cirrhosis.", "results_summary": "99% of patients achieved sustained virological response at 12 weeks, with a favorable safety profile and no alanine aminotransferase elevations or treatment discontinuations due to adverse events. The most common adverse events were fatigue (19%) and headache (14%).", "population_specificity": "Patients aged 18+ with HCV genotype 1, 2, 4, 5, or 6 infection and compensated cirrhosis, either treatment-naive or previously treated.", "effective_dosage": "Glecaprevir (300 mg) coformulated with pibrentasvir (120 mg) once daily.", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:32.283327+00:00"}
{"study_id": 104247, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the hypoglycemia risk between basal insulin peglispro (BIL) and insulin glargine (GL) after a double-dose error in patients with type 2 diabetes.", "results_summary": "BIL showed a significantly lower risk of clinically significant hypoglycemia compared to GL (6.6% vs. 35.5%). However, BIL was associated with higher serum alanine aminotransferase and triglyceride levels.", "population_specificity": "Patients with type 2 diabetes previously treated with insulin (N=68).", "effective_dosage": "Individualized once-nightly doses, with a double dose administered during the inpatient phase.", "study_duration": "3 weeks per crossover period, with a 7-day inpatient stay.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:32.933998+00:00"}
{"study_id": 104250, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop a scoring system to predict whether rheumatoid arthritis (RA) patients would respond better to tocilizumab (TCZ) or tumor necrosis factor inhibitors (TNF-i) based on laboratory indices, including alanine aminotransferase (ALT).", "results_summary": "The study found that ALT levels, along with other laboratory indices, correlated with TCZ efficacy in RA patients. A scoring system based on these indices (including ALT) effectively predicted better treatment responses, with higher scores favoring TCZ over TNF-i.", "population_specificity": "98 RA patients (initial analysis) and an additional 228 patients (validation study).", "effective_dosage": "Not specified", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:34.113736+00:00"}
{"study_id": 104251, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to compare the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy versus TDF plus entecavir (ETV) combination therapy in patients with chronic hepatitis B (CHB) who had a poor response to ETV, including effects on alanine aminotransferase normalization.", "results_summary": "The study found no significant differences in alanine aminotransferase normalization, viral suppression, or other clinical outcomes between TDF monotherapy and TDF-ETV combination therapy at weeks 24 and 48, suggesting comparable efficacy.", "population_specificity": "Patients with chronic hepatitis B (CHB) who had a poor response to entecavir (ETV).", "effective_dosage": "Not specified", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:35.549216+00:00"}
{"study_id": 104249, "supplement_id": 863, "safety_score": "70", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of asunaprevir + daclatasvir combination therapy in cirrhotic and non-cirrhotic patients with HCV genotype 1b, focusing on sustained viral response (SVR) and liver function improvement.", "results_summary": "The therapy achieved a 96% SVR24 rate in both cirrhotic and non-cirrhotic patients, with significant improvements in liver function markers like alanine aminotransferase and AFP levels in cirrhotic patients. However, cirrhotic patients experienced higher rates of adverse events and HCC recurrence/development compared to non-cirrhotic patients.", "population_specificity": "Compensated cirrhotic and non-cirrhotic patients with HCV genotype 1b without resistance-associated substitutions (RASs) at L31 and Y93.", "effective_dosage": "100 mg asunaprevir twice daily plus 60 mg daclatasvir once daily.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:35.594462+00:00"}
{"study_id": 104252, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were reviewing emerging therapeutic pharmaceuticals for COPD, including compounds targeting myristoylated alanine-rich C kinase substrate (MARCKS), but did not specifically investigate alanine itself.", "results_summary": "The abstract mentions myristoylated alanine-rich C kinase substrate (MARCKS) as a potential therapeutic target for COPD, but no specific results regarding alanine's effects are provided.", "population_specificity": "COPD patients (general, no specific subgroup mentioned for alanine-related research).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:36.244140+00:00"}
{"study_id": 104253, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the therapeutic effects of oral glutathione (not Alanine) in patients with nonalcoholic fatty liver disease (NAFLD), focusing on changes in alanine aminotransferase (ALT) levels and other clinical parameters.", "results_summary": "Oral glutathione (300 mg/day) significantly reduced ALT levels, triglycerides, non-esterified fatty acids, and ferritin in NAFLD patients after 4 months of treatment. ALT responders were younger and had less severe diabetes compared to non-responders.", "population_specificity": "34 patients with NAFLD diagnosed via ultrasonography.", "effective_dosage": "300 mg/day", "study_duration": "4 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:38.623665+00:00"}
{"study_id": 104254, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine if HLA-DRB1*07:01 allele carriage is a risk biomarker for lapatinib-induced liver injury, as indicated by serum alanine aminotransferase (ALT) elevations.", "results_summary": "The study found that HLA-DRB1*07:01 carriage was associated with ALT elevations in lapatinib-treated patients, with an odds ratio of 6.5 and significant statistical association (P=3 \u00d7 10).", "population_specificity": "Patients with advanced breast cancer receiving adjuvant lapatinib, alone or in combination with trastuzumab and taxanes.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:39.922302+00:00"}
{"study_id": 104256, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "To investigate the effects of hydrogen-rich water (HRW) treatment on preventing ethanol-induced early fatty liver in mice, with a focus on potential mechanisms involving acyl ghrelin and inflammatory cytokines.", "results_summary": "HRW protected against chronic ethanol-induced liver injury by inducing acyl ghrelin, suppressing pro-inflammatory cytokines (TNF-\u03b1 and IL-6), and promoting anti-inflammatory cytokines (IL-10 and IL-22), thereby activating antioxidant enzymes to combat oxidative stress.", "population_specificity": "Mice with ethanol-induced early fatty liver.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:40.497918+00:00"}
{"study_id": 104255, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 35, "quality_score": 75, "study_goal": "To evaluate the effect of silymarin on serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma glutamyl transpeptidase (\u03b3GT) in patients with liver diseases.", "results_summary": "Silymarin minimally reduced serum levels of ALT and AST, but the reduction was not clinically relevant. The study concluded that more rigorous methodological designs are needed for future research.", "population_specificity": "Adult and elderly patients of both sexes with liver diseases.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:40.700941+00:00"}
{"study_id": 104257, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to quantify the risk of acute liver injury associated with antidepressant use, particularly focusing on alanine aminotransferase levels.", "results_summary": "The study found that current use of antidepressants, especially citalopram, was associated with a significantly increased risk of liver injury, with alanine aminotransferase being a key marker. The risk of antidepressant-induced liver injury may be underestimated in pre-marketing trials.", "population_specificity": "Inpatient adults admitted to nine Italian hospitals with acute liver injury or other acute clinical conditions not related to the liver.", "effective_dosage": "Not specified", "study_duration": "Exposure evaluated within 90 days prior to the first sign/symptom of liver injury.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:42.665670+00:00"}
{"study_id": 104258, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy (HEV-NA) and compare it with NA cases without HEV infection.", "results_summary": "The study found that HEV-NA cases were predominantly anicteric, had bilateral involvement, and more extensive damage to the brachial plexus compared to non-HEV NA cases. HEV RNA was detected in serum and CSF, suggesting a causal relationship between HEV and NA.", "population_specificity": "Patients with neuralgic amyotrophy (NA) from 11 centers across 7 European countries, including both HEV-positive and HEV-negative cases.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:44.072910+00:00"}
{"study_id": 104259, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of sleeve gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB) on liver function, including alanine aminotransferase (ALT) levels, in bariatric patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that SG significantly improved ALT levels in patients with NAFLD after 12 months, while RYGB initially worsened liver function markers (e.g., INR) but returned to baseline by 12 months. SG showed better early safety and efficacy in liver function improvement compared to RYGB.", "population_specificity": "Morbidly obese patients with NAFLD or NASH undergoing bariatric surgery.", "effective_dosage": "Not available", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:44.335477+00:00"}
{"study_id": 104260, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were comparing the efficacy and safety of transarterial chemoembolization (TACE) using miriplatin versus epirubicin in patients with unresectable hepatocellular carcinoma (HCC), not specifically studying alanine.", "results_summary": "The study found no significant difference in overall survival between miriplatin and epirubicin TACE, but miriplatin was associated with fewer hepatic adverse events, including elevated alanine aminotransferase.", "population_specificity": "Patients with unresectable hepatocellular carcinoma (HCC).", "effective_dosage": "Not specified for alanine.", "study_duration": "Median follow-up was approximately 3 years (1111 days for miriplatin, 1127 days for epirubicin).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:44.866108+00:00"}
{"study_id": 104261, "supplement_id": 863, "safety_score": "60", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers examined the potential liver injury effects of high, sustained oral doses of green tea extract (GTE), focusing on changes in alanine aminotransferase (ALT) levels.", "results_summary": "The study found that GTE consumption significantly increased ALT levels by 5.4 U/L and aspartate aminotransferase by 3.8 U/L compared to placebo, indicating potential liver injury effects.", "population_specificity": "1,021 women with normal baseline liver enzyme levels (513 in GTE arm, 508 in placebo arm).", "effective_dosage": "High, sustained oral dose (specific amount not mentioned).", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:47.016165+00:00"}
{"study_id": 104262, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy of ipragliflozin versus pioglitazone in patients with type 2 diabetes complicated by nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Both ipragliflozin and pioglitazone showed similar beneficial effects on NAFLD and glycemic control, but ipragliflozin additionally reduced body weight and abdominal fat area significantly.", "population_specificity": "Patients with type 2 diabetes and NAFLD (n=66).", "effective_dosage": "Ipragliflozin 50 mg (frequency not specified).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:47.629197+00:00"}
{"study_id": 104264, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare hepatitis B virus (HBV) infection status and chronic hepatitis B (cHB) between HIV-infected and HIV-uninfected individuals in a multinational clinical trial.", "results_summary": "The study found that HBV infection status did not differ by HIV infection status, but HIV co-infection was associated with isolated HBcAb and a trend of increased HBV DNA. In HIV-positive individuals, cHB was associated with mild transaminase elevations (including alanine aminotransferase) and a trend toward lower CD4.", "population_specificity": "HIV-infected and HIV-uninfected individuals from 7 HBV-endemic countries.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:48.918903+00:00"}
{"study_id": 104263, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the maximum tolerated dose, safety, pharmacokinetics, and antitumour activity of LY2780301 (a dual AKT/p70S6K inhibitor) in combination with gemcitabine in patients with advanced/metastatic solid tumours harboring PI3K/AKT/mTOR pathway alterations.", "results_summary": "The study found that LY2780301 combined with gemcitabine had manageable toxicity and showed encouraging antitumour activity in patients with PI3K/AKT/mTOR pathway alterations. The maximum tolerated dose was LY2780301 500 mg QD with gemcitabine 750 mg/m\u00b2.", "population_specificity": "Patients with advanced/metastatic solid tumours and molecular alterations in the PI3K/AKT/mTOR pathway (e.g., PI3K mutations/amplifications, PTEN inactivation).", "effective_dosage": "LY2780301 400 or 500 mg QD orally; gemcitabine 750 or 1000 mg/m\u00b2 intravenously.", "study_duration": "Up to 14 cycles (cycle duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:51.628952+00:00"}
{"study_id": 104266, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of direct-acting antivirals (DAAs) for treating hepatitis C virus (HCV)-infected renal transplant recipients (RTRs), including the impact on liver function markers like alanine aminotransferase (ALT).", "results_summary": "DAAs were highly efficacious, with 98.3% of RTRs achieving sustained virological response within 12 weeks. Liver function improved significantly posttreatment (ALT and AST levels), but allograft function remained stable. Common adverse events were mild, while severe events were rare.", "population_specificity": "HCV-infected renal transplant recipients (360 participants across six studies).", "effective_dosage": "Not specified", "study_duration": "24-week treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:52.883488+00:00"}
{"study_id": 104267, "supplement_id": 863, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of Dl-3n-butylphthalide (NBP) for treating progressive cerebral infarction (PCI).", "results_summary": "NBP significantly improved NIHSS and Barthel index scores compared to placebo, indicating reduced disability and better daily living outcomes. Adverse events included elevated alanine aminotransferase and aspartate aminotransferase, but these were not statistically significant.", "population_specificity": "304 inpatients with progressive cerebral infarction.", "effective_dosage": "200 mg of NBP soft capsules orally, 3 times daily, 15 minutes before each meal.", "study_duration": "21 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:52.917645+00:00"}
{"study_id": 104265, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy and safety of peginterferon \u03b1-2a alone versus peginterferon \u03b1-2a plus adjusted-dose ribavirin in treating chronic HCV infection in hemodialysis patients, with a focus on virologic response and dropout rates.", "results_summary": "The study found that peginterferon \u03b1-2a plus ribavirin resulted in better early virologic response (80% vs. 47%) and sustained virologic response (85% vs. 50%) compared to peginterferon \u03b1-2a alone, with no significant differences in safety parameters like anemia or side effects. Alanine aminotransferase levels decreased in both groups compared to baseline, with no intergroup differences.", "population_specificity": "Hemodialysis patients with chronic HCV infection in Saudi Arabia.", "effective_dosage": "Adjusted dose of ribavirin (specific amount not detailed).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:53.468120+00:00"}
{"study_id": 104268, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the association between therapeutic hypothermia (TH) and hepatic biomarkers, including alanine aminotransferase (ALT), in infants with hypoxic ischemic encephalopathy (HIE).", "results_summary": "Therapeutic hypothermia was associated with lower peak ALT concentrations and delayed CRP responses, suggesting a potential modulation of hepatic injury in infants with HIE. The severity of HIE was significantly correlated with hepatic biomarkers, indicating liver injury as part of multiorgan dysfunction.", "population_specificity": "Infants with moderate-severe hypoxic ischemic encephalopathy (HIE).", "effective_dosage": "Not specified", "study_duration": "First postnatal week", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:53.508941+00:00"}
{"study_id": 104270, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of nutritional and physical activity interventions, including the impact on alanine transaminase levels, in managing paediatric nonalcoholic fatty liver disease.", "results_summary": "Vitamin E was ineffective at improving alanine transaminase levels, while omega-3 fatty acids decreased hepatic fat content. Probiotics showed mixed results, and reduced fructose consumption did not improve primary outcomes.", "population_specificity": "Paediatric patients with nonalcoholic fatty liver disease.", "effective_dosage": "Not specified for alanine transaminase-related interventions.", "study_duration": "Not specified for alanine transaminase-related interventions.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:55.510405+00:00"}
{"study_id": 104269, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to analyze the distribution of HCV genotypes and subtypes in a diverse US patient population and assess their association with geographic and demographic factors, including alanine aminotransferase levels.", "results_summary": "The study found that GT3 HCV patients had significantly higher alanine aminotransferase levels (>2 times the upper limit of normal) compared to other genotypes, while GT4&6 patients showed higher Fibrosis-4 Index scores indicative of cirrhosis.", "population_specificity": "Over 8,000 HCV-infected patients from four large US health systems, including racially diverse groups (African American, Asian/other, white).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:55.573291+00:00"}
{"study_id": 104271, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the potential for discontinuing tenofovir disoproxil fumarate (TDF) therapy in HBeAg-negative chronic hepatitis B patients, focusing on sustained virological response and HBsAg loss.", "results_summary": "Of the patients who stopped TDF therapy, 62% remained off-therapy for 144 weeks, with 43% achieving either HBsAg loss or HBV DNA suppression below 2,000 IU/ml. The study suggests potential for stopping long-term TDF therapy in non-cirrhotic HBeAg-negative patients under strict surveillance.", "population_specificity": "Non-cirrhotic HBeAg-negative chronic hepatitis B patients who had received TDF for \u22654 years with suppressed HBV DNA for \u22653.5 years.", "effective_dosage": "Not specified (TDF monotherapy, exact dosage not mentioned).", "study_duration": "144 weeks (post-treatment follow-up).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:59.063902+00:00"}
{"study_id": 104272, "supplement_id": 863, "safety_score": "20", "efficacy_score": 10, "quality_score": 75, "study_goal": "The researchers aimed to determine the safety, maximum tolerated dose, and efficacy of mithramycin in inhibiting EWS-FLI1 in patients with refractory Ewing sarcoma, with a focus on hepatotoxicity markers like alanine aminotransferase (ALT).", "results_summary": "The study found that mithramycin caused reversible grade 4 ALT/AST elevation at higher doses, preventing safe administration of doses required to inhibit EWS-FLI1. No clinical responses were observed, and the trial was closed due to inability to achieve desired drug exposure.", "population_specificity": "Children and adults with refractory solid tumors, specifically Ewing sarcoma.", "effective_dosage": "Adults: 25 \u00b5g/kg/dose (initial), reduced to 17.5 \u00b5g/kg/dose; Children: 13 \u00b5g/kg/dose.", "study_duration": "7 days per 28-day cycle.", "interactions": "Dexamethasone pretreatment was used to mitigate toxicity.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:01.486066+00:00"}
{"study_id": 104273, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to compare the efficacy of icotinib versus whole-brain irradiation (WBI) with or without chemotherapy in patients with EGFR-mutant NSCLC and multiple brain metastases, not to evaluate Alanine.", "results_summary": "The study found that icotinib significantly prolonged intracranial progression-free survival compared to WBI, but it did not assess Alanine's effects.", "population_specificity": "Patients with EGFR-mutant NSCLC and multiple brain metastases.", "effective_dosage": "Not applicable (study did not evaluate Alanine).", "study_duration": "Not applicable (study did not evaluate Alanine).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:01.530059+00:00"}
{"study_id": 104274, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the outcomes of right lobe living donor liver transplantation (LDLT) by comparing donors aged \u226555 years to those <55 years.", "results_summary": "The study compared outcomes of right lobe LDLT between elderly (\u226555 years) and younger (<55 years) donors, focusing on selection criteria for elderly donors and matching criteria for recipients. No specific results regarding Alanine were reported.", "population_specificity": "Elderly (\u226555 years) and younger (<55 years) living liver donors and their matched recipients.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:01.675477+00:00"}
{"study_id": 104275, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the SFLI scoring system and the Child-Pugh grading system in predicting postoperative mortality in patients with hepatocellular carcinoma (HCC), including the role of alanine transaminase (ALT) as a biochemical marker.", "results_summary": "The study found that the SFLI scoring system, which includes ALT among other markers, was more effective than the Child-Pugh classification in predicting postoperative mortality in HCC patients, with higher AUC values (88.2% vs. 10.2%). Mortality rates increased significantly with higher grading in both systems.", "population_specificity": "114 patients with hepatocellular carcinoma (HCC) who underwent surgical treatment.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:02.186786+00:00"}
{"study_id": 104278, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to study the long-term outcomes, including virological and clinical relapse rates, after stopping antiviral therapy in immune-tolerant chronic hepatitis B patients.", "results_summary": "All patients experienced virological relapse shortly after treatment cessation, and half developed clinical relapse. HBeAg seroconversion was rare, regardless of treatment reinitiation.", "population_specificity": "Immune-tolerant chronic hepatitis B patients", "effective_dosage": "Not specified", "study_duration": "4 years of treatment, followed by 4 years of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:02.967639+00:00"}
{"study_id": 104276, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of modified-FOLFIRINOX (including reduced doses of Oxaliplatin and Irinotecan) in Chinese patients with metastatic pancreatic cancer, not specifically focusing on Alanine.", "results_summary": "The study found that modified-FOLFIRINOX had a response rate of 32.5% and frequent grade 3/4 adverse events, including alanine aminotransferase elevation (14.5%). No treatment-related deaths were observed.", "population_specificity": "Chinese patients with metastatic pancreatic cancer (n=62, with 40 evaluated).", "effective_dosage": "Not specified for Alanine (study focused on modified-FOLFIRINOX: no Fluorouracil bolus, 85% Oxaliplatin, and 75% Irinotecan).", "study_duration": "Treatment administered between April 2014 and April 2017 (exact duration per patient not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:03.488236+00:00"}
{"study_id": 104277, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the antidiabetic efficacy and safety of Balanites aegyptiaca extract (BE) in elderly type 2 diabetes patients, including its effects on plasma alanine transaminase levels.", "results_summary": "The study found that BE capsules significantly reduced plasma alanine transaminase by 42.6%, alongside improvements in glycaemic markers and lipid profiles, with no reported adverse effects or hypoglycaemia.", "population_specificity": "30 type 2 diabetes Egyptian patients, divided into placebo and treatment groups based on sex, age, and body mass index.", "effective_dosage": "400 mg/day (incorporated in hard gelatine capsules).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:03.902005+00:00"}
{"study_id": 104282, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the novel LiMAx test compared to conventional liver function markers as covariates of drug clearance in liver failure patients using linezolid as a model drug.", "results_summary": "The study assessed liver function in 28 patients with varying degrees of liver failure under steady-state linezolid therapy, but no specific results regarding Alanine were reported.", "population_specificity": "28 patients with different degrees of liver failure in the intensive care unit.", "effective_dosage": "600 mg linezolid twice daily.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:09.033975+00:00"}
{"study_id": 104279, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of luseogliflozin and metformin on liver fat deposition and metabolic parameters in type 2 diabetes patients with non-alcoholic fatty liver disease (NAFLD), including the impact on alanine aminotransferase (ALT) levels.", "results_summary": "The study found that luseogliflozin significantly reduced liver fat deposition (measured by L/S ratio) compared to metformin, along with greater improvements in visceral fat area, HbA1c, and body mass index. Changes in ALT, fasting glucose, CPR, and CPR index were not significant in either group.", "population_specificity": "Type 2 diabetes patients with NAFLD (n=32).", "effective_dosage": "Luseogliflozin (2.5 mg daily) or metformin (1500 mg daily, newly or additionally administered).", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:09.208615+00:00"}
{"study_id": 104283, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine whether quantitative HBsAg levels could predict the severity of liver disease in HBeAg-negative genotype E patients, with a focus on alanine transaminase (ALT) as a biochemical marker.", "results_summary": "The study found that advanced fibrosis patients had higher ALT levels, and qHBsAg levels were lower in more advanced liver fibrosis, but there was no correlation between qHBsAg and HBV DNA levels.", "population_specificity": "259 HBeAg-negative CHB treatment-naive genotype E patients (median age 38 years, 61% male).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:10.548142+00:00"}
{"study_id": 104281, "supplement_id": 863, "safety_score": "85", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine whether supplements, including ornithine \u03b1-ketoglutarate (which contains alanine precursors), could affect plasma levels of glutamine and ammonia, urinary excretion of Krebs cycle intermediates, and clinical outcomes in patients with propionic acidemia.", "results_summary": "Plasma alanine levels significantly increased with anaplerotic agents, normalizing ammonia buffering by glutamate, but no significant changes in ammonia or glutamine levels were observed. Motor and cognitive development remained severely delayed, though hospitalizations decreased post-study.", "population_specificity": "3 patients with propionic acidemia.", "effective_dosage": "Ornithine \u03b1-ketoglutarate (400mg/kg per day).", "study_duration": "Each supplement was administered for four weeks, with citrate continued for 30 weeks and a 2-year extension.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:10.550633+00:00"}
{"study_id": 104285, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the impact of nanocurcumin on liver function, including alanine transaminase levels, in obese patients with NAFLD.", "results_summary": "The abstract does not provide specific results regarding alanine transaminase or other liver function markers; it only mentions that these will be measured at the beginning and end of the study.", "population_specificity": "Obese patients with non-alcoholic fatty liver disease (NAFLD) diagnosed via ultrasonography.", "effective_dosage": "Not specified for alanine; nanocurcumin dosage was 40 mg capsules twice daily with meals.", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:11.426903+00:00"}
{"study_id": 104286, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the effectiveness of combined therapy with rosuvastatin and ezetimibe for hypercholesterolemia, focusing on the timing of administration (morning vs. evening).", "results_summary": "The abstract does not provide specific results regarding Alanine's effects, as the study primarily focuses on lipid-lowering therapy outcomes.", "population_specificity": "200 patients with hypercholesterolemia ineffectively treated with statins for at least 6 weeks.", "effective_dosage": "Not specified for Alanine.", "study_duration": "12 weeks (6 weeks for each administration timing).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:11.881362+00:00"}
{"study_id": 104284, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the impact of rimonabant (a CB1 antagonist) on alanine aminotransferase (ALT) levels and hepatic inflammatory markers in obese women with PCOS.", "results_summary": "Rimonabant reduced ALT levels independently of weight loss, while other treatments (orlistat, metformin, pioglitazone) had no effect on ALT. No changes were observed in hepatic inflammatory cytokine profiles across interventions.", "population_specificity": "Obese women with polycystic ovary syndrome (PCOS) without non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Rimonabant (20 mg once daily), orlistat (120 mg three times daily), metformin (500 mg three times daily), pioglitazone (45 mg once daily).", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:12.420408+00:00"}
{"study_id": 104288, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the drug-drug interaction and safety of glecaprevir and pibrentasvir coadministration in healthy volunteers.", "results_summary": "Coadministration of glecaprevir and pibrentasvir resulted in increased pibrentasvir exposures without significant changes in glecaprevir exposures, with no clinically significant laboratory abnormalities reported.", "population_specificity": "Healthy volunteers", "effective_dosage": "Glecaprevir (100-1200 mg once daily), pibrentasvir (40-200 mg once daily)", "study_duration": "14 days (7 days alone, 7 days in combination)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:17.615916+00:00"}
{"study_id": 104287, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 35, "quality_score": 75, "study_goal": "The researchers aimed to determine whether elevated alanine transaminase levels were associated with secondary infections in patients bitten by Bothrops snakes.", "results_summary": "Elevated alanine transaminase (>44 IU/L) was independently associated with an increased risk of secondary infections in snakebite victims (AOR = 2.52, p = 0.037). The study did not evaluate alanine as a therapeutic intervention but identified it as a risk marker.", "population_specificity": "Patients bitten by Bothrops snakes in the Western Brazilian Amazon.", "effective_dosage": "Not applicable (alanine transaminase was measured, not administered).", "study_duration": "7-day follow-up period.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:17.758869+00:00"}
{"study_id": 104289, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the effectiveness and safety of statins, not specifically Alanine, in children with heterozygous familial hypercholesterolemia.", "results_summary": "The study found that statins reduced LDL cholesterol levels in children with familial hypercholesterolemia without significant safety concerns in the short term, but long-term safety remains unknown. Alanine aminotransferase levels did not differ between treated and placebo groups.", "population_specificity": "Children up to 18 years old with heterozygous familial hypercholesterolemia.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median 24 weeks (range from six weeks to two years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:18.780443+00:00"}
{"study_id": 104280, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the impact of lifestyle intervention on sCD163 levels in NAFLD patients and its association with liver biomarkers, including alanine aminotransferase (ALT).", "results_summary": "The study found a significant decrease in sCD163 levels after a three-month lifestyle intervention, correlating with reductions in ALT and HOMA-IR, but levels returned to baseline by 12-24 months.", "population_specificity": "126 adult patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "3-month intervention with follow-ups at 12 and 24 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:19.132293+00:00"}
{"study_id": 104290, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify key residues in the amyloid core region of IAPP that influence its interaction with A\u03b240(42) peptides, using alanine substitution to assess their roles.", "results_summary": "The study found that single aromatic/hydrophobic residues in IAPP are critical for its cross-interaction with A\u03b240(42), but none alone affects IAPP self-assembly. Simultaneous substitution of four residues with alanine significantly impaired both self-assembly and hetero-assembly with A\u03b240(42).", "population_specificity": "In vitro study (no human or animal subjects specified).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:19.257857+00:00"}
{"study_id": 104291, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to examine physiological and biochemical responses to exercise, including potential effects on alcohol consumption and HPA-axis activity, in heavy drinkers.", "results_summary": "The 8-week exercise intervention reduced alcohol consumption and \u03b3-GT levels while improving fitness, but did not significantly alter hormonal responses related to the HPA-axis.", "population_specificity": "Heavy drinkers (Age: 30.3\u00b13.5yrs; BMI: 28.4\u00b10.86kg/m\u00b2).", "effective_dosage": "Not specified (supervised exercise training).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:19.660535+00:00"}
{"study_id": 104292, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers examined the utility of a customized online nutrition guidance system in maintaining diet therapy continuity for patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that body weight and serum alanine aminotransferase levels significantly decreased from baseline, and the system's visualization tools and email encouragement helped maintain patient motivation.", "population_specificity": "Seven patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "90 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:20.211131+00:00"}
{"study_id": 104293, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and efficacy of salazosulfapyridine (SASP) in combination with cisplatin and pemetrexed for treating advanced non-squamous non-small-cell lung cancer, not specifically studying alanine.", "results_summary": "The study found that SASP combined with cisplatin-pemetrexed had a maximum tolerated dose of 3 g/day and a recommended dose of 1.5 g/day, with an overall response rate of 26.7% and median progression-free survival of 11.7 months. Alanine aminotransferase elevation (grade 3) was observed as a dose-limiting toxicity in one patient at 1.5 g/day SASP.", "population_specificity": "Chemotherapy-na\u00efve patients with advanced non-squamous non-small-cell lung cancer.", "effective_dosage": "SASP doses of 1.5 g/day, 3 g/day, and 4.5 g/day were tested.", "study_duration": "Duration of intervention not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:24.048286+00:00"}
{"study_id": 104294, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to characterize natural changes in liver inflammation and its association with hepatitis B viremia during pregnancy and postpartum, with a focus on alanine aminotransferase levels.", "results_summary": "Alanine aminotransferase levels decreased during pregnancy but increased sharply in the first month postpartum. Higher baseline hepatitis B virus titer was strongly associated with hepatic flare during early postpartum.", "population_specificity": "Chronic hepatitis B (CHB) pregnant women (n=1097).", "effective_dosage": "Not specified for alanine. Antiviral therapies included telbivudine and tenofovir.", "study_duration": "Follow-up to 52 weeks postpartum.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:26.020918+00:00"}
{"study_id": 104295, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers sought to determine the incidence, predictors, and clinical significance of HCV reactivation during cancer treatment in HCV-infected patients.", "results_summary": "HCV reactivation occurred in 23% of HCV-infected patients receiving cancer treatment, with most cases having an unremarkable clinical course, though reactivation could affect the cancer treatment plan. The study suggests HCV infection should not contraindicate cancer therapy, but close monitoring is needed for regimens associated with reactivation.", "population_specificity": "HCV-infected patients receiving cancer treatment.", "effective_dosage": "Not mentioned", "study_duration": "Study period was from November 2012 to July 2016 (intervention duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:26.775221+00:00"}
{"study_id": 104298, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the association between high serum gamma-glutamyl transferase (GGT) levels and mortality in patients with chronic kidney disease (CKD).", "results_summary": "The study found that high GGT levels were independently associated with increased mortality in CKD patients, alongside higher comorbidity burden and specific biochemical profiles. Elevated GGT and alkaline phosphatase (ALP) levels were predictive of mortality in adjusted models.", "population_specificity": "Adults with stage 4-5 CKD not yet on dialysis (mean age 65\u00b115 years).", "effective_dosage": "Not available", "study_duration": "Median survival time was 74 months (observational period).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.577439+00:00"}
{"study_id": 104299, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to examine the variation in laboratory reference intervals for alanine aminotransferase (ALT) and other analytes across Canadian clinical laboratories.", "results_summary": "The study found significant variability in ALT reference intervals, particularly in pediatric populations, and noted that reference interval variation exceeded test result variation for most analytes. Differences in reference sample measurements were also observed, especially for ALT.", "population_specificity": "Pediatric and adult populations in Canadian clinical laboratories.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.888713+00:00"}
{"study_id": 104296, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the impact of a high-protein meal replacement (HPMR) on weight, metabolic, lipid, and inflammatory parameters, including alanine aminotransferase levels, in overweight/obese Asian Indians.", "results_summary": "The study found that the HPMR intervention led to significant improvements in obesity measures, metabolic parameters, and hepatic transaminases, including a 22.0% reduction in alanine aminotransferase levels. The intervention also improved lipid profiles, inflammatory markers, and insulin sensitivity compared to the control diet.", "population_specificity": "Overweight/obese Asian Indian men and women.", "effective_dosage": "Not specified (high-protein meal replacement composition not detailed).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:28.006035+00:00"}
{"study_id": 104300, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effect of genistein supplementation on non-alcoholic fatty liver disease (NAFLD) as a hepatic manifestation of metabolic syndrome.", "results_summary": "Genistein supplementation reduced insulin resistance, oxidative stress, inflammatory markers, and improved fat metabolism in NAFLD patients, but did not significantly affect BMI, fasting blood glucose, ALT, or AST levels.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD) (n = 82, split into genistein and placebo groups).", "effective_dosage": "250 mg genistein daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:28.251190+00:00"}
{"study_id": 104297, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were assessing the efficacy and safety of trabectedin versus dacarbazine in women with uterine leiomyosarcoma (uLMS), focusing on disease control and adverse events, including transient alanine aminotransferase elevations.", "results_summary": "The study found that trabectedin improved progression-free survival (PFS) compared to dacarbazine but showed no significant difference in overall survival (OS). Transient alanine aminotransferase elevations were among the grade 3/4 adverse events observed in the trabectedin group.", "population_specificity": "Women with uterine leiomyosarcoma (uLMS) who had received prior anthracycline therapy.", "effective_dosage": "Trabectedin 1.5mg/m\u00b2 (specific frequency not detailed in abstract).", "study_duration": "Not specified in abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:29.502604+00:00"}
{"study_id": 104301, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety, tolerability, and efficacy of the FLT3 inhibitor gilteritinib in patients with relapsed or refractory acute myeloid leukaemia, not specifically Alanine.", "results_summary": "The study found that gilteritinib was well tolerated with a maximum tolerated dose of 300 mg/day, showed consistent FLT3 inhibition, and achieved responses in 40% of patients. Adverse events included febrile neutropenia, anemia, and elevated liver enzymes, but the study did not focus on Alanine.", "population_specificity": "Adults aged 18 or older with relapsed or refractory acute myeloid leukaemia.", "effective_dosage": "20 mg, 40 mg, 80 mg, 120 mg, 200 mg, 300 mg, or 450 mg once daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:34.689541+00:00"}
{"study_id": 104302, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of oral cholic acid in patients with bile acid synthesis disorders (BASDs) due to single enzyme defects (SEDs) or Zellweger spectrum disorders (ZSDs).", "results_summary": "Cholic acid significantly improved urine bile acid metabolite scores, liver chemistries (serum aspartate aminotransferase, alanine aminotransferase), and weight percentiles. Liver biopsies showed stable findings or histologic improvement, and the safety profile was favorable with no serious adverse events or deaths reported.", "population_specificity": "Patients with BASDs due to SEDs (63 patients) or ZSDs (22 patients).", "effective_dosage": "10 to 15 mg\u00b7kg\u00b7day orally.", "study_duration": "18 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:35.246960+00:00"}
{"study_id": 104303, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the association of the rs4803217 SNP with the severity of chronic hepatitis C (CHC) and its predictive value for sustained virological response (SVR) and relapse in patients treated with PEG-IFN-\u03b1 and ribavirin.", "results_summary": "The rs4803217 SNP was not associated with CHC severity (inflammation, fibrosis, viral load, or biochemical parameters) but was found to be a strong, independent predictor of SVR and relapse in HCV genotype 1-infected patients.", "population_specificity": "196 treatment-na\u00efve Polish patients (82 women, 114 men, aged 20-64) with HCV genotype 1 infection.", "effective_dosage": "Not specified", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:35.547590+00:00"}
{"study_id": 104305, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the impact of the single tablet regimen EVG/COBI/FTC/TDF on liver and kidney toxicity in ART-experienced or na\u00efve patients, not specifically Alanine.", "results_summary": "The study found a significant decline in eGFR in patients initiating EVG/COBI/FTC/TDF, with no significant worsening at 12 months vs. 6 months. Patients with chronic HCV infection had a higher risk of abnormal liver tests.", "population_specificity": "ART-experienced or na\u00efve patients, including those with HCV co-infection.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Evaluated at baseline, 6 months, and 12 months.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:36.373334+00:00"}
{"study_id": 104304, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether the S267F variant on the NTCP gene was associated with response to pegylated interferon (PEG-IFN) in patients with chronic HBV infection, particularly focusing on alanine aminotransferase (ALT) normalization.", "results_summary": "The S267F GA variant was associated with sustained ALT normalization in HBeAg-positive patients (OR = 3.25, P=0.02) and showed a tendency for improved virological response and HBsAg loss post-treatment. No association was found in HBeAg-negative patients.", "population_specificity": "257 patients with chronic HBV infection, predominantly genotype C (84.9%), from 13 Thai tertiary hospitals.", "effective_dosage": "Not specified", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:36.552538+00:00"}
{"study_id": 104307, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and clinical benefits of oral D-galactose supplementation in patients with PGM1-CDG, a subtype of congenital disorders of glycosylation.", "results_summary": "D-galactose supplementation improved or normalized abnormal baseline laboratory results, enhanced transferrin glycosylation, and increased antithrombin-III levels. In vitro studies confirmed improved cellular glycosylation and normalized nucleotide sugar levels following treatment.", "population_specificity": "Nine patients with PGM1-CDG (eight compliant).", "effective_dosage": "Increased to 1.5 g/kg/day (maximum 50 g/day) in three increments.", "study_duration": "18 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.153422+00:00"}
{"study_id": 104306, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the baseline characteristics and treatment needs of patients with chronic hepatitis B (CHB) in Ethiopia, including the role of alanine aminotransferase (ALT) levels in assessing liver health.", "results_summary": "The study found that the majority of CHB patients were HBeAg negative and had normal ALT levels (\u226440 U/L). However, 29.5% had significant fibrosis, and 24.7% required antiviral treatment, with 62.2% of those having cirrhosis.", "population_specificity": "Adults (\u226518 years) with chronic hepatitis B in Ethiopia.", "effective_dosage": "Not specified for Alanine (ALT was measured, not administered).", "study_duration": "Not specified for Alanine (study duration not detailed in abstract).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:38.370292+00:00"}
{"study_id": 104308, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy of folic acid versus silymarin in reducing liver enzymes (including alanine aminotransferase, ALT) in children with drug-induced liver injury (DILI) due to antiepileptic therapy.", "results_summary": "Both folic acid and silymarin significantly reduced liver enzymes, but folic acid showed a stronger decrease in ALT, AST, and GGT levels and a higher percentage of normalized enzyme values compared to silymarin. No adverse reactions or rebound elevations in liver enzymes were observed in either group.", "population_specificity": "55 children with epilepsy experiencing DILI due to antiepileptic treatment.", "effective_dosage": "Folic acid (1 mg per day), silymarin (5 mg/kg per day).", "study_duration": "One month of treatment, followed by three months of follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:38.823137+00:00"}
{"study_id": 104311, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of undifferentiated human mesenchymal stem cells, in vitro differentiated mesenchymal stem cells, and adult hepatocytes on liver function and fibrosis in a chronic liver failure model.", "results_summary": "All cell-treated groups showed improved liver function markers (alanine aminotransferase, aspartate aminotransferase, albumin, bilirubin), with the hepatocyte-treated group performing best. Fibrosis improvement was most evident in the undifferentiated mesenchymal stem cell-treated group.", "population_specificity": "CCL4-induced cirrhotic rat model.", "effective_dosage": "Not specified.", "study_duration": "3 months post-transplant.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:43.485156+00:00"}
{"study_id": 104312, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop and validate a machine learning model using routine clinical and laboratory parameters, including alanine aminotransferase, to detect NAFLD in the general population.", "results_summary": "The study identified six predictors, including alanine aminotransferase, for detecting NAFLD and found the ridge regression model to be simple and robust for excluding NAFLD patients in epidemiological studies.", "population_specificity": "922 subjects from a population screening study, divided into training and validation groups.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:43.885239+00:00"}
{"study_id": 104310, "supplement_id": 863, "safety_score": "75", "efficacy_score": null, "quality_score": 80, "study_goal": "The researchers aimed to investigate the safety, tolerability, and pharmacokinetics of OM3-CA (containing EPA and DHA) in healthy male Japanese and white subjects.", "results_summary": "OM3-CA was well tolerated, with alanine aminotransferase increase being the most common adverse event in Japanese subjects and diarrhea in white subjects. Pharmacokinetic profiles of EPA and DHA were comparable between Japanese and white subjects.", "population_specificity": "Healthy male Japanese and white subjects.", "effective_dosage": "2 or 4 g/day OM3-CA.", "study_duration": "Not specified (single and multiple doses).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.217960+00:00"}
{"study_id": 104309, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were comparing the efficacy and safety of ceritinib versus single-agent chemotherapy in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed following crizotinib and platinum-based doublet chemotherapy.", "results_summary": "The study found that ceritinib significantly improved median progression-free survival compared to chemotherapy (5.4 months vs. 1.6 months). Adverse events, including increased alanine aminotransferase concentration, were more frequent in the ceritinib group, but treatment-related serious adverse events were similar between groups.", "population_specificity": "Patients aged at least 18 years with ALK-rearranged stage IIIB or IV non-small-cell lung cancer who had received previous chemotherapy and crizotinib and had subsequent disease progression.", "effective_dosage": "Oral ceritinib 750 mg per day fasted (in 21-day treatment cycles).", "study_duration": "Median follow-up was 16.5 months (IQR 11.5-21.4).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.937847+00:00"}
{"study_id": 104314, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the long-term safety of statins in patients with prediabetes/T2DM and NASH, not specifically Alanine.", "results_summary": "The study found that statin therapy was safe in patients with prediabetes/T2DM and NASH, with no significant adverse effects on liver histology or hepatic insulin resistance. Plasma alanine aminotransferase levels were higher in statin nonusers, but no major safety concerns were identified.", "population_specificity": "Patients with biopsy-proven NASH and prediabetes/T2DM (n=101, 86 receiving statins).", "effective_dosage": "Not specified for Alanine.", "study_duration": "Up to 36 months.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:45.675002+00:00"}
{"study_id": 104316, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy of rescue therapy (ETV or LDT) after interferon failure versus de novo therapy with ETV or LDT in chronic HBV patients, focusing on virological response, HBeAg seroconversion, and ALT normalization.", "results_summary": "The study found that rescue therapy with ETV or LDT after interferon failure resulted in faster virologic response and higher HBeAg seroconversion rates compared to de novo therapy, with the IFN-ETV group showing the most significant improvements.", "population_specificity": "Patients with chronic hepatitis B virus (HBV) infection (n=180).", "effective_dosage": "Not specified", "study_duration": "104 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:47.341109+00:00"}
{"study_id": 104313, "supplement_id": 863, "safety_score": "20", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers were assessing the efficacy and safety of buparlisib (a pan-PI3K inhibitor) combined with fulvestrant in postmenopausal women with advanced breast cancer, including evaluating PI3K pathway activation as a biomarker.", "results_summary": "The study found that buparlisib plus fulvestrant improved progression-free survival compared to placebo plus fulvestrant, particularly in patients with PI3K pathway-activated tumors. However, significant safety concerns were noted, including elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.", "population_specificity": "Postmenopausal women aged 18+ with hormone receptor-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer who had progressed on aromatase inhibitor therapy.", "effective_dosage": "Buparlisib (100 mg/day orally) plus fulvestrant (500 mg intramuscularly on days 1 and 15 of cycle 1, then day 1 of subsequent 28-day cycles).", "study_duration": "Median follow-up was not explicitly stated, but progression-free survival was assessed over several months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:47.886646+00:00"}
{"study_id": 104315, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess the safety and preliminary efficacy of oral X-82, a tyrosine kinase inhibitor, for treating neovascular age-related macular degeneration (AMD).", "results_summary": "The study found that X-82 was associated with reversible adverse events, including elevated liver enzymes, but participants who completed the treatment had lower-than-expected anti-VEGF injection rates and maintained or improved visual acuity. Some participants demonstrated sustained retinal thickness reductions without additional anti-VEGF injections.", "population_specificity": "Thirty-five participants with neovascular AMD, predominantly white (33/35), mean age 76.8 years.", "effective_dosage": "50 mg alternate days, 50 mg daily, 100 mg alternate days, 100 mg daily, 200 mg daily, and 300 mg daily.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:48.099539+00:00"}
{"study_id": 104318, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to identify patterns in metabolic parameters, including alanine aminotransferase levels, in transgender adolescents receiving cross-sex hormones.", "results_summary": "The study found that estrogen use was associated with lower alanine aminotransferase levels, while testosterone use did not significantly affect this parameter. No other significant changes in metabolic parameters related to alanine were reported.", "population_specificity": "Transgender adolescents aged 14 to 25 years (72 female-to-male and 44 male-to-female subjects).", "effective_dosage": "Not specified", "study_duration": "Measurements were taken before therapy, at 1-3 months, 4-6 months, and beyond 6 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:52.778447+00:00"}
{"study_id": 104317, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were evaluating the safety and efficacy of daclatasvir (DCV) and asunaprevir (ASV) combination therapy for hemodialysis patients with genotype 1 HCV infections, not specifically studying alanine.", "results_summary": "The study found that DCV/ASV combination therapy was highly effective (95.9% SVR12 rate) and safe for hemodialysis patients with genotype 1 HCV infections, including those with advanced liver fibrosis or resistance-associated variants. Adverse events leading to discontinuation were rare (3.3%).", "population_specificity": "Hemodialysis patients with genotype 1 HCV infection in Japan.", "effective_dosage": "Not specified for alanine.", "study_duration": "Treatment period was between November 2014 and March 2016 (exact duration not specified).", "interactions": "None mentioned for alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:53.236150+00:00"}
{"study_id": 104320, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the addition of temsirolimus or dinutuximab to irinotecan-temozolomide in patients with relapsed or refractory neuroblastoma, with alanine aminotransferase levels as an exclusion criterion for eligibility.", "results_summary": "One patient was excluded due to elevated alanine aminotransferase levels, but the study did not assess alanine's effects. The primary focus was on the efficacy and safety of the drug combinations for neuroblastoma treatment.", "population_specificity": "Children with relapsed or refractory neuroblastoma or ganglioneuroblastoma.", "effective_dosage": "Not specified for alanine.", "study_duration": "Median follow-up was 1.26 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:54.058804+00:00"}
{"study_id": 104319, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess the association between elevated serum alanine aminotransferase (ALT) levels and disease progression (cirrhosis, hepatocellular carcinoma, and mortality) in chronic hepatitis B patients.", "results_summary": "Elevated serum alanine aminotransferase (ALT) levels were significantly associated with progression to liver cirrhosis (p=0.0059) and increased mortality (p=0.0039). High viral load and ALT elevations were also linked to hepatocellular carcinoma development and poorer prognosis.", "population_specificity": "247 chronic hepatitis B virus (HBV) patients treated at a tertiary hospital in Brazil (67.2% male, 74.1% HBeAg negative, 41% with cirrhosis).", "effective_dosage": "Not specified", "study_duration": "Retrospective analysis covering patients treated between January 2000 and January 2015 (up to 15 years).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:54.342706+00:00"}
{"study_id": 104324, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare biomarkers, including Alanine, with albuminuria for identifying early Fabry nephropathy and assessing diagnostic accuracy for CKD stage\u22652.", "results_summary": "The study found significant increases in biomarkers, including Alanine, in Fabry patients, even without nephropathy, and stronger correlations with CKD progression than albuminuria.", "population_specificity": "78 Fabry patients and 25 healthy controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:55.376949+00:00"}
{"study_id": 104322, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to examine the association between serum alanine aminotransferase (ALT) levels and hypertension in a rural elderly Chinese population.", "results_summary": "Increased serum ALT levels were positively associated with hypertension, particularly in women, with the association being significant in those with central obesity or nondrinking habits. No significant association was found between aspartate aminotransferase (AST) levels and hypertension.", "population_specificity": "Chinese rural elderly population (2,174 participants with normal aminotransferase levels and no excessive drinking).", "effective_dosage": "Not specified", "study_duration": "Cross-sectional study (single time point)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:55.406171+00:00"}
{"study_id": 104321, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the relationship between regorafenib exposure and efficacy in patients with hepatocellular carcinoma (HCC) who had disease progression during sorafenib treatment, with a secondary focus on potential correlations with treatment-emergent adverse events.", "results_summary": "The study found no meaningful relationship between regorafenib exposure and treatment-emergent adverse events, but higher exposure categories showed longer median overall survival and time-to-progression. However, within regorafenib-treated patients, increasing exposure did not significantly improve efficacy outcomes.", "population_specificity": "Patients with intermediate or advanced hepatocellular carcinoma (HCC) who had disease progression during sorafenib treatment.", "effective_dosage": "160mg regorafenib once daily (3 weeks on/1 week off in a 4-week cycle).", "study_duration": "Until disease progression, death, or unacceptable toxicity.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:55.626190+00:00"}
{"study_id": 104323, "supplement_id": 863, "safety_score": "75", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to assess the safety and potential efficacy of L-serine in slowing ALS progression and investigate environmental factors linked to ALS cases.", "results_summary": "The study found that L-serine was generally safe at doses up to 15 g twice daily, with a 34% reduction in ALS progression rate. ALS cases were non-randomly distributed, suggesting environmental pollutant exposure may contribute to ALS etiology.", "population_specificity": "20 ALS patients in the phase I trial; broader analysis included ALS cases in New Hampshire, Vermont, and Florida.", "effective_dosage": "0.5 to 15 g twice daily", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:56.256588+00:00"}
{"study_id": 104325, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to monitor how treatment of acutely ruptured ACL affects biomarkers of inflammation and proteolytic degradation, including alanine, over 5 years.", "results_summary": "The study did not report specific findings related to alanine's effects, focusing instead on inflammatory cytokines and other biomarkers. No differences between groups were noted for ARGS-aggrecan in synovial fluid and serum or CTX-II and NTX-I in urine over 5 years.", "population_specificity": "119 subjects with acute ACL injury from the KANON-trial.", "effective_dosage": "Not specified", "study_duration": "5 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:00.767974+00:00"}
{"study_id": 104329, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers compared the effects of weight loss induced by liraglutide versus a structured lifestyle intervention in obese adults with NAFLD.", "results_summary": "The abstract does not mention any findings related to Alanine.", "population_specificity": "Obese adults (BMI \u226530 kg/m\u00b2) with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:01.884754+00:00"}
{"study_id": 104327, "supplement_id": 863, "safety_score": "75", "efficacy_score": null, "quality_score": 80, "study_goal": "The researchers aimed to characterize normal inter- and intraindividual variability in safety parameters, including alanine aminotransferase levels, in healthy volunteers administered placebo.", "results_summary": "The study found that alanine aminotransferase elevations occurred in 7.9% of healthy volunteers, with 5.1 events per 100 measures above the upper limit of normal. The most common adverse event was headache, occurring in 7.9% of participants.", "population_specificity": "Normal healthy volunteers (355 participants)", "effective_dosage": "Not specified", "study_duration": "Median duration of 28 days (range 2 to 63 days)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:02.371683+00:00"}
{"study_id": 104333, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to assess the efficacy and safety of hepatoprotectant prophylaxis, including its effects on alanine transaminase (ALT) levels, in patients receiving anti-TB drugs.", "results_summary": "Hepatoprotective agents significantly reduced ALT and AST levels after 4 weeks of treatment and decreased drug-induced liver injury (DILI) cases, with no significant increase in adverse events compared to controls.", "population_specificity": "Patients receiving anti-TB treatment.", "effective_dosage": "Not specified", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:02.931049+00:00"}
{"study_id": 104328, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to compare the clinical outcomes and safety parameters, including alanine aminotransferase level changes, between hydrophilic and lipophilic statins in patients with coronary artery disease.", "results_summary": "The study found that lipophilic statins had a higher risk of alanine aminotransferase elevation compared to hydrophilic statins, but no significant differences were observed in other safety parameters like drug discontinuation or muscle symptoms. The efficacy of both statin types was similar for most cardiovascular outcomes, except for lower CV hospitalization with lipophilic statins.", "population_specificity": "Patients with coronary artery disease (11,697 participants from 11 RCTs).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Mean follow-up of 14 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:03.498352+00:00"}
{"study_id": 104326, "supplement_id": 863, "safety_score": "70", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to assess whether peg-interferon-alfa-2a combined with nucleotide analogues (adefovir or tenofovir) could induce HBsAg loss in patients with chronic hepatitis B and low viral load.", "results_summary": "The study found no significant difference in HBsAg loss between combination therapy groups (4% in each) and the no-treatment group (0%). Adverse events were common, primarily attributed to peg-IFN, with serious adverse events reported in all groups.", "population_specificity": "HBsAg-positive, HBeAg-negative patients with chronic hepatitis B and low viral load, including treatment-naive and treatment-experienced individuals with ALT <5\u00d7ULN.", "effective_dosage": "peg-IFN 180 \u03bcg/week plus adefovir 10 mg/day or tenofovir disoproxil fumarate 245 mg/day.", "study_duration": "48 weeks of treatment, with follow-up to 72 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:03.682498+00:00"}
{"study_id": 104330, "supplement_id": 863, "safety_score": "60", "efficacy_score": 80, "quality_score": 85, "study_goal": "To investigate the effect of fasiglifam on glycaemic control in people with type 2 diabetes mellitus (T2DM).", "results_summary": "Fasiglifam effectively reduced HbA1c from baseline over 24 weeks in participants with T2DM. The incidence of treatment-emergent adverse events (TEAEs) was higher in the fasiglifam groups, but serious adverse events were low and similar between groups; ALT elevations were observed only in the fasiglifam groups.", "population_specificity": "People with T2DM and HbA1c \u22657.0% and \u226410.5% who had received only diet and exercise treatment for \u226512 weeks prior to screening.", "effective_dosage": "25 mg or 50 mg", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:04.420466+00:00"}
{"study_id": 106660, "supplement_id": 881, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review the role of oxidative stress in neurological diseases and evaluate the potential of antioxidant therapies for conditions like stroke and Alzheimer's disease.", "results_summary": "The abstract highlights that oxidative stress is a key factor in neurological diseases and suggests antioxidant therapies as a potential treatment target, though specific efficacy results are not detailed.", "population_specificity": "Neurological disease patients (e.g., stroke, Alzheimer's disease)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:11.632473+00:00"}
